Peripheral Olfactory Ensheathing Cells	1
Scar and Cavity Formation	47
Regeneration after Spinal Cord Injury LEANNE M. RAMER ,1,2 EDMUND AU ,1 MIRANDA W. RICHTER ,1 JIE LIU ,1,2 WOLFRAM TETZLAFF ,1,2 AND A. JANE ROSKAMS1 * 1Department of Zoology , University of British Columbia , Vancouver , British Columbia V6T 1Z4 , Canada 2International Collaboration	85
Regeneration after Spinal Cord Injury LEANNE M. RAMER ,1,2 EDMUND AU ,1 MIRANDA W. RICHTER ,1 JIE LIU ,1,2 WOLFRAM TETZLAFF ,1,2 AND A. JANE ROSKAMS1	85
Regeneration	85
Spinal Cord	104
Injury LEANNE M. RAMER ,1,2 EDMUND AU ,1 MIRANDA W. RICHTER	116
Injury LEANNE M. RAMER ,1,2 EDMUND	116
AU ,1 MIRANDA W. RICHTER	151
,1	174
JIE LIU ,1,2 WOLFRAM TETZLAFF ,1,2 AND A. JANE ROSKAMS1	177
JIE LIU	177
,1,2 WOLFRAM TETZLAFF ,1,2 AND A. JANE ROSKAMS1	184
,1,2 WOLFRAM TETZLAFF ,1,2	184
A. JANE ROSKAMS1	214
1Department of Zoology , University of British Columbia , Vancouver , British Columbia V6T 1Z4 , Canada 2International Collaboration	232
1Department	232
Zoology , University of British Columbia , Vancouver , British Columbia V6T 1Z4 , Canada 2International Collaboration	247
Zoology , University	247
British Columbia , Vancouver , British Columbia V6T 1Z4 , Canada 2International Collaboration	270
British Columbia , Vancouver , British Columbia V6T 1Z4	270
Canada 2International Collaboration	325
Repair Discoveries , University of British Columbia , Vancouver , British Columbia V6T 1Z4 , Canada ABSTRACT Bridging of a lesion site	364
Repair Discoveries	364
University of British Columbia , Vancouver , British Columbia V6T 1Z4 , Canada ABSTRACT Bridging of a lesion site	384
University	384
British Columbia , Vancouver , British Columbia V6T 1Z4 , Canada ABSTRACT Bridging of a lesion site	398
British Columbia , Vancouver , British Columbia V6T 1Z4	398
Canada ABSTRACT Bridging of a lesion site	453
Canada ABSTRACT Bridging	453
a lesion site	482
local damage	511
an environment permissive for regeneration	534
an environment permissive	534
regeneration	564
both primary components of a successful strategy to repair spinal cord injury -LRB- SCI -RRB-	581
both primary components	581
a successful strategy to repair spinal cord injury -LRB- SCI -RRB-	608
spinal cord injury -LRB- SCI -RRB-	640
spinal cord injury	640
SCI	660
Olfactory ensheathing cells -LRB- OECs -RRB-	666
Olfactory ensheathing cells	666
OECs	695
prime candidates for autologous transplantation to bridge this gap	705
prime candidates	705
autologous transplantation	726
this gap	763
little	777
their mechanism of action	809
their mechanism	809
action	828
addition	839
OECs from the accessible lamina propria -LRB- LP -RRB- of the olfactory mucosa	849
OECs	849
the accessible lamina propria -LRB- LP -RRB-	859
the accessible lamina propria	859
LP	890
the olfactory mucosa	897
a more viable source in humans but have yet to be tested for their ability to promote regeneration in established SCI models	922
a more viable source	922
humans but have yet to be tested for their ability to promote regeneration in established SCI models	946
humans	946
their ability to promote regeneration in established SCI models	983
regeneration	1008
established SCI models	1024
mouse LP-OECs expressing green fluorescent protein -LRB- GFP -RRB- transplanted directly into both rat and mouse dorsolateral spinal cord lesion sites	1054
mouse LP-OECs	1054
green fluorescent protein -LRB- GFP -RRB- transplanted directly into both rat and mouse dorsolateral spinal cord lesion sites	1079
green fluorescent protein	1079
GFP	1106
directly into both rat and mouse dorsolateral spinal cord lesion sites	1124
both rat and mouse dorsolateral spinal cord lesion	1138
rat	1143
mouse dorsolateral spinal cord lesion	1151
limited migration	1207
host astrocytes	1243
a new transitional zone	1270
the lesion border	1297
LP-OECs	1316
extensive migration of host Schwann cells	1337
extensive migration	1337
host Schwann cells	1360
the central nervous system repair zone	1384
angiogenesis	1437
a biological scaffold for repair	1461
a biological scaffold	1461
repair	1487
This novel environment created by transplanted and host glia within the spinal cord	1495
This novel environment	1495
transplanted and host glia within the spinal cord	1529
transplanted	1529
host glia within the spinal cord	1546
host glia	1546
the spinal cord	1563
cavity and scar formation	1588
multiple sensory and motor axons	1650
the lesion site	1700
Sixty days	1717
rat SCI	1734
serotonin - and tyrosine hydroxylase-positive axons	1743
serotonin	1743
tyrosine hydroxylase-positive axons	1758
the lesion	1810
the distal cord	1826
axotomized rubrospinal axons	1852
a xenotransplant paradigm	1904
LP-OECs work collaboratively with host glial cells to create an environment to ameliorate local damage and simultaneously	1931
LP-OECs work	1931
host glial cells to create an environment to ameliorate local damage and simultaneously	1965
host glial cells	1965
an environment to ameliorate local damage	1992
local damage	2021
a regenerative response in multiple axonal populations	2061
a regenerative response	2061
multiple axonal populations	2088
significant evidence demonstrating some functional regeneration in rodent models of spinal cord injury -LRB- SCI -RRB-	2126
significant evidence	2126
some functional regeneration in rodent models of spinal cord injury -LRB- SCI -RRB-	2161
some functional regeneration	2161
rodent models of spinal cord injury -LRB- SCI -RRB-	2193
rodent models	2193
spinal cord injury -LRB- SCI -RRB-	2210
spinal cord injury	2210
SCI	2230
human SCI	2236
permanent neurologic deficits	2263
yet to benefit from the variety of therapies suggested by successful animal experimentation -LRB- Amar and Levy , 1999 ; Edgerton and Roy , 2002 ; Fawcett , 2002 -RRB-	2301
the variety of therapies suggested by successful animal experimentation -LRB- Amar and Levy , 1999 ; Edgerton and Roy , 2002 ; Fawcett , 2002 -RRB-	2321
the variety	2321
therapies suggested by successful animal experimentation -LRB- Amar and Levy , 1999 ; Edgerton and Roy , 2002 ; Fawcett , 2002 -RRB-	2336
therapies	2336
successful animal experimentation -LRB- Amar and Levy , 1999 ; Edgerton and Roy , 2002 ; Fawcett , 2002 -RRB-	2359
successful animal experimentation	2359
Amar and Levy , 1999 ; Edgerton and Roy , 2002 ; Fawcett , 2002	2394
Amar and Levy	2394
Amar	2394
Levy	2403
1999 ; Edgerton and Roy	2409
1999	2409
Edgerton and Roy	2415
2002 ; Fawcett , 2002	2433
2002	2433
Fawcett , 2002	2439
Fawcett	2439
2002	2448
Axons confined within the central nervous system -LRB- CNS -RRB-	2455
Axons	2455
the central nervous system	2477
CNS	2505
appropriate central targets -LRB- Ramon y Cajal , 1928 -RRB-	2558
appropriate central targets	2558
Ramon y Cajal , 1928	2587
Ramon y Cajal	2587
1928	2602
contrast	2612
peripheral nervous system -LRB- PNS -RRB- injury in adult rodents and humans	2622
peripheral nervous system -LRB- PNS -RRB- injury	2622
PNS	2649
adult rodents and humans	2664
successful axonal regeneration	2710
the adult mammalian olfactory system	2745
successful re-targeting of axons in both the PNS and CNS portions of the primary olfactory neuraxis	2792
successful re-targeting	2792
axons in both the PNS and CNS portions of the primary olfactory neuraxis	2819
axons	2819
both the PNS and CNS portions	2828
the PNS	2833
CNS portions	2845
the primary olfactory neuraxis	2861
Adult olfactory receptor neurons -LRB- ORNs -RRB-	2905
Adult olfactory receptor neurons	2905
ORNs	2939
turnover -- apoptosis-induced replacement -- from an endogenous progenitor pool	2966
turnover -- apoptosis-induced replacement --	2966
turnover	2966
apoptosis-induced replacement	2975
an endogenous progenitor pool	3010
their axons	3045
a PNS-CNS boundary	3066
the olfactory bulb	3123
birth	3148
adulthood -LRB- Graziadei et al. , 1978 ; Schwob , 2002 -RRB-	3165
adulthood	3165
Graziadei	3176
et al. , 1978 ; Schwob , 2002	3186
et al.	3186
1978 ; Schwob	3194
1978	3194
Schwob	3200
2002	3208
Successful axonal growth and regeneration in the adult olfactory system	3215
Successful axonal growth	3215
regeneration in the adult olfactory system	3244
regeneration	3244
the adult olfactory system	3260
large part	3305
a unique population of glial cells -- olfactory ensheathing cells -LRB- OECs -RRB-	3320
a unique population	3320
glial cells -- olfactory ensheathing cells -LRB- OECs -RRB-	3343
glial cells	3343
olfactory ensheathing cells	3355
OECs	3384
OECs	3391
ORN axons	3406
their exit point	3421
the basal lamina of the olfactory mucosa -LRB- lamina propria OECs ; LP-OECs -RRB-	3441
the basal lamina	3441
the olfactory mucosa -LRB- lamina propria OECs ; LP-OECs -RRB-	3461
the olfactory mucosa	3461
lamina propria OECs ; LP-OECs	3483
lamina propria OECs	3483
LP-OECs	3504
the cribriform plate	3522
the nerve fiber layer of the olfactory bulb -LRB- Doucette , 1991 -RRB-	3553
the nerve fiber layer	3553
the olfactory bulb -LRB- Doucette , 1991 -RRB-	3578
the olfactory bulb	3578
Doucette , 1991	3598
Doucette	3598
1991	3608
OECs	3615
they	3640
antigenic and morphologic characteristics of astrocytes , Schwann cells , and oligodendrocytes	3653
antigenic and morphologic characteristics	3653
astrocytes , Schwann cells , and oligodendrocytes	3698
astrocytes	3698
Schwann cells	3710
oligodendrocytes	3729
an array of trophic factors , transcription factors , and extracellular matrix molecules more typical of embryonic glia -LRB- reviewed by Ramon-Cueto and Avila , 1998 ; Gudino-Cabrera and Nieto-Sampedro , 1999 ; Chuah and West , 2002 ; Au and Roskams , 2003 -RRB-	3759
an array	3759
trophic factors , transcription factors , and extracellular matrix molecules more typical	3771
trophic factors	3771
transcription factors	3788
extracellular matrix molecules more typical	3815
extracellular matrix molecules	3815
embryonic glia -LRB- reviewed by Ramon-Cueto and Avila , 1998 ; Gudino-Cabrera and Nieto-Sampedro , 1999 ; Chuah and West , 2002 ; Au and Roskams , 2003 -RRB-	3862
Ramon-Cueto and Avila , 1998 ; Gudino-Cabrera and Nieto-Sampedro , 1999 ; Chuah and West , 2002 ; Au and Roskams , 2003	3890
Ramon-Cueto	3890
Avila , 1998 ; Gudino-Cabrera and Nieto-Sampedro , 1999 ; Chuah and West , 2002 ; Au and Roskams , 2003	3906
Avila , 1998	3906
Avila	3906
1998	3913
Gudino-Cabrera and Nieto-Sampedro , 1999	3919
Gudino-Cabrera and Nieto-Sampedro	3919
1999	3954
Chuah and West , 2002	3960
Chuah and West	3960
2002	3976
Au and Roskams , 2003	3982
Au and Roskams	3982
2003	3998
they	4013
axonal regeneration	4026
the CNS portion of the olfactory system	4063
the CNS portion	4063
the olfactory system	4082
olfactory bulb-derived ensheathing cells -LRB- OB-OECs -RRB-	4104
olfactory bulb-derived ensheathing cells	4104
OB-OECs	4146
significant promise	4204
regeneration	4237
spinal cord lesion -LRB- reviewed by Bartolomei and Greer , 2000 ; Bunge , 2002 -RRB-	4256
spinal cord lesion	4256
Bartolomei and Greer , 2000 ; Bunge , 2002	4288
Bartolomei and Greer	4288
2000 ; Bunge , 2002	4310
2000	4310
Bunge , 2002	4316
Bunge	4316
2002	4323
OBOECs	4330
regeneration of sensory and descending axons to varying degrees	4356
regeneration	4356
sensory and descending axons to varying degrees	4372
sensory	4372
descending axons to varying degrees	4384
descending axons	4384
varying degrees	4404
the site of thoracic spinal transection , fine electrolytic lesion , hemisection , or moderate contusion in adult rat	4441
the site	4441
thoracic spinal transection , fine electrolytic lesion , hemisection , or moderate contusion in adult rat	4453
thoracic spinal transection	4453
fine electrolytic lesion	4482
hemisection	4508
moderate contusion in adult rat	4524
moderate contusion	4524
adult rat	4546
Li et al. , 1997 ; Ramon-Cueto et al. , 1998 ; Nash et al. , 2002 ; Takami et al. , 2002	4557
Li	4557
et al. , 1997 ; Ramon-Cueto et al. , 1998 ; Nash et al. , 2002 ; Takami et al. , 2002	4560
et al. , 1997	4560
et al.	4560
1997	4568
Ramon-Cueto et al. , 1998	4574
Ramon-Cueto	4574
et al. , 1998	4586
et al.	4586
1998	4594
Nash et al. , 2002	4600
Nash	4600
et al. , 2002	4605
et al.	4605
2002	4613
Takami et al. , 2002	4619
Takami	4619
et al. , 2002	4626
et al.	4626
2002	4634
the OEC transplantation field	4656
widely different protocols for preparing OECs , minimal accounting for how cellular purity or heterogeneity may change with time in culture or frequency of passage , and a variety of delivery techniques -LRB- reviewed in Franklin , 2002 -RRB-	4710
widely different protocols for preparing OECs , minimal accounting for how cellular purity or heterogeneity may change with time in culture or frequency of passage , and a variety of delivery techniques	4710
widely different protocols for preparing OECs	4710
widely different protocols	4710
OECs	4751
minimal accounting for how cellular purity or heterogeneity may change with time in culture or frequency of passage	4757
minimal accounting	4757
cellular purity or heterogeneity	4784
cellular purity	4784
heterogeneity	4803
time	4833
culture or frequency of passage	4841
culture or frequency	4841
passage	4865
a variety of delivery techniques	4878
a variety	4878
delivery techniques	4891
Franklin , 2002	4924
Franklin	4924
2002	4934
It	4941
the integration , fate , and migration patterns of transplanted OECs due to problems with marking the cells stably enough	5000
the integration	5000
fate	5017
migration patterns of transplanted OECs due to problems with marking the cells stably enough	5027
migration patterns	5027
transplanted OECs due to problems with marking the cells stably enough	5049
transplanted OECs	5049
problems	5074
the cells	5096
them	5130
the complex environment of a spinal cord	5138
the complex environment	5138
a spinal cord	5165
This tracking	5180
an essential component of understanding OEC mechanisms of action to optimize their use in a transplantation approach	5207
an essential component	5207
OEC mechanisms of action	5247
OEC mechanisms	5247
action	5265
their use	5284
a transplantation approach	5297
OECs	5325
a defining molecular marker and share multiple antigenic and morphologic characteristics	5335
a defining molecular marker	5335
share multiple antigenic and morphologic characteristics	5367
share	5367
multiple antigenic and morphologic characteristics	5373
endogenous glia	5429
Schwann cells -LRB- Barnett et al. , 1993 -RRB-	5464
Schwann cells	5464
Barnett	5479
et al. , 1993	5487
et al.	5487
1993	5495
Dye-loading of cells before transplantation	5502
Dye-loading	5502
cells before transplantation	5517
cells	5517
transplantation	5530
several cases	5563
vital dyes	5582
leak	5604
phagocytic cells , which are themselves highly migratory , thus confounding interpretation of these data -LRB- Iwashita et al. , 2000 ; Ruitenberg et al. , 2002 -RRB-	5637
phagocytic cells	5637
interpretation of these data -LRB- Iwashita et al. , 2000 ; Ruitenberg et al. , 2002 -RRB-	5711
interpretation	5711
these data -LRB- Iwashita et al. , 2000 ; Ruitenberg et al. , 2002 -RRB-	5729
these data	5729
Iwashita	5741
et al. , 2000 ; Ruitenberg et al. , 2002	5750
et al.	5750
2000 ; Ruitenberg et al.	5758
2000	5758
Ruitenberg et al.	5764
Ruitenberg	5764
et al.	5775
2002	5783
OB-OECs	5804
transplantation paradigms	5841
their use	5872
acute SCI models	5913
Their peripheral counterparts , LP-OECs ,	5931
Their peripheral counterparts	5931
LP-OECs	5962
a more accessible source for potential autotransplantation in human SCI	5981
a more accessible source	5981
potential autotransplantation in human SCI	6010
potential autotransplantation	6010
human SCI	6043
untested in animal models of SCI	6064
untested	6064
animal models of SCI	6076
animal models	6076
SCI	6093
strips	6106
suspensions of olfactory mucosa -LRB- containing a highly heterogeneous mixture of different cells -RRB-	6128
suspensions	6128
olfactory mucosa -LRB- containing a highly heterogeneous mixture of different cells -RRB-	6143
a highly heterogeneous mixture of different cells	6172
a highly heterogeneous mixture	6172
different cells	6206
regeneration of brainstem and sensory axons -LRB- Lu et al. , 20012002 -RRB-	6247
regeneration	6247
brainstem and sensory axons -LRB- Lu et al. , 20012002 -RRB-	6263
brainstem and sensory axons	6263
Lu	6292
et al. , 20012002	6295
et al.	6295
20012002	6303
these data	6318
the initiation of human trials using autotransplantation of uncharacterized LPOECs in patients with chronic SCI -LRB- http://www	6349
the initiation	6349
human trials using autotransplantation of uncharacterized LPOECs in patients with chronic SCI -LRB- http://www	6367
human trials	6367
autotransplantation of uncharacterized LPOECs	6386
autotransplantation	6386
uncharacterized LPOECs	6409
patients with chronic SCI -LRB- http://www	6435
patients	6435
chronic SCI -LRB- http://www	6449
chronic	6449
SCI -LRB- http://www	6457
ausbioinfo.com/news/articles/2002-07-12_108.php	6474
we	6530
LP-OECs	6568
endogenous enhanced green fluorescent protein -LRB- GFP -RRB- into acute spinal cord injury in immunesuppressed rats and mice	6587
endogenous enhanced green fluorescent protein	6587
GFP	6634
acute spinal cord injury in immunesuppressed rats and mice	6644
acute spinal cord injury	6644
immunesuppressed rats and mice	6672
GFP fluorescence	6717
species-specific antibodies	6739
we	6768
transplanted LP-OECs	6795
the regeneration environment of the spinal cord in both xeno - and allotransplant SCI models	6824
the regeneration environment of the spinal cord in both xeno	6824
the regeneration environment	6824
the spinal cord in both	6856
the spinal cord	6856
allotransplant SCI models	6890
we	6923
LP-OECs	6938
a novel interaction between host glial cells	6965
a novel interaction	6965
host glial cells	6993
the spinal cord lesion environment	7021
a new transitional environment	7067
multiple axonal tracts	7104
a regeneration response	7148
MATERIALS AND METHODS	7174
Preparation of OECs from GFP mice OECs were harvested and cultured from the olfactory mucosa of homozygous transgenic mice expressing eGFP -LRB- GFP-U-NAGY ; generated by Andreas Nagy , U. Toronto ; kind gift of Frank Jirik , U. Calgary -RRB- , driven by a combination of betta-actin promoter and CMV-enhancer	7196
Preparation	7196
OECs from GFP mice	7211
OECs	7211
GFP mice	7221
OECs	7230
the olfactory mucosa of homozygous transgenic mice expressing eGFP -LRB- GFP-U-NAGY ; generated by Andreas Nagy , U. Toronto ; kind gift of Frank Jirik , U. Calgary -RRB- , driven by a combination of betta-actin promoter and CMV-enhancer	7268
the olfactory mucosa	7268
homozygous transgenic mice expressing eGFP -LRB- GFP-U-NAGY ; generated by Andreas Nagy , U. Toronto ; kind gift of Frank Jirik , U. Calgary -RRB- , driven by a combination of betta-actin promoter and CMV-enhancer	7292
homozygous transgenic mice	7292
eGFP -LRB- GFP-U-NAGY ; generated by Andreas Nagy , U. Toronto ; kind gift of Frank Jirik , U. Calgary -RRB- , driven by a combination of betta-actin promoter and CMV-enhancer	7330
eGFP -LRB- GFP-U-NAGY ; generated by Andreas Nagy , U. Toronto ; kind gift of Frank Jirik , U. Calgary -RRB-	7330
eGFP	7330
GFP-U-NAGY ; generated by Andreas Nagy , U. Toronto ; kind gift of Frank Jirik , U. Calgary	7336
GFP-U-NAGY	7336
generated by Andreas Nagy , U. Toronto ; kind gift of Frank Jirik , U. Calgary	7348
Andreas Nagy , U. Toronto	7361
Andreas Nagy	7361
U. Toronto	7375
kind gift of Frank Jirik , U. Calgary	7387
kind gift	7387
Frank Jirik , U. Calgary	7400
Frank Jirik	7400
U. Calgary	7413
a combination of betta-actin promoter and CMV-enhancer	7436
a combination	7436
betta-actin promoter and CMV-enhancer	7453
Au and Roskams	7492
2003	7508
Each culture	7515
10 to 12 dissected postnatal day -LRB- P -RRB- P5 -- P7 mouse olfactory turbinates , digested with 1.2 mg/ml collagenase D	7546
10 to 12	7546
postnatal day -LRB- P -RRB- P5 -- P7 mouse olfactory turbinates , digested with 1.2 mg/ml collagenase D	7565
postnatal day -LRB- P -RRB- P5 -- P7 mouse olfactory turbinates	7565
postnatal day -LRB- P -RRB- P5	7565
postnatal day	7565
P	7580
P5	7583
P7 mouse olfactory turbinates	7586
P7 mouse	7586
olfactory turbinates	7595
1.2 mg/ml collagenase D	7631
3 U/ml dispase	7656
I	7671
30 µg/ml hyaluronidase , and 100 U/ml DNAse I for 1 hour at 37 °C ,	7674
30 µg/ml hyaluronidase	7674
100 U/ml DNAse I for 1 hour at 37 °C	7702
100 U/ml DNAse I	7702
1 hour at 37 °C	7723
1 hour	7723
37 °C	7733
centrifugation and plating -LRB- all enzymes from Roche Diagnostics , Laval , Quebec , Canada -RRB-	7746
centrifugation and plating	7746
all enzymes from Roche Diagnostics	7774
all enzymes	7774
Roche Diagnostics	7791
Laval , Quebec , Canada	7810
Laval	7810
Quebec , Canada	7817
Cells	7834
4 days in vitro -LRB- DIV -RRB- in MEM-d-valine with 10 % heat-inactivated fetal bovine serum and 1 % -LRB- 100 U/ml -RRB- penicillin/streptomycin -LRB- pen/strep ; Life Technologies , Rockville , MD -RRB- , before anti-Thy 1.1 -- mediated complement lysis as previously described to remove contaminating fibroblasts -LRB- Au and Roskams , 2003 -RRB-	7868
4 days in vitro -LRB- DIV -RRB- in MEM-d-valine with 10 % heat-inactivated fetal bovine serum and 1 % -LRB- 100 U/ml -RRB- penicillin/streptomycin -LRB- pen/strep ; Life Technologies , Rockville , MD -RRB- , before anti-Thy 1.1	7868
4 days	7868
-LRB- DIV -RRB- in MEM-d-valine with 10 % heat-inactivated fetal bovine serum and 1 % -LRB- 100 U/ml -RRB- penicillin/streptomycin -LRB- pen/strep ; Life Technologies , Rockville , MD -RRB- , before anti-Thy 1.1	7884
-LRB- DIV -RRB- in MEM-d-valine with 10 % heat-inactivated fetal bovine serum	7884
-LRB- DIV -RRB-	7884
MEM-d-valine with 10 % heat-inactivated fetal bovine serum	7893
MEM-d-valine	7893
10 % heat-inactivated fetal bovine serum	7911
1 % -LRB- 100 U/ml -RRB- penicillin/streptomycin -LRB- pen/strep ; Life Technologies , Rockville , MD -RRB- , before anti-Thy 1.1	7955
1 % -LRB- 100 U/ml -RRB- penicillin/streptomycin	7955
1 %	7955
100 U/ml	7959
penicillin/streptomycin	7969
pen/strep ; Life Technologies	7994
pen/strep	7994
Life Technologies	8005
Rockville , MD	8024
Rockville	8024
MD	8035
anti-Thy 1.1	8047
mediated complement lysis as previously described to remove contaminating fibroblasts -LRB- Au and Roskams , 2003 -RRB-	8061
mediated complement lysis	8061
contaminating fibroblasts	8121
Au and Roskams	8148
2003	8164
Thy1 .1 antibody-mediated complement lysis	8171
Thy1	8171
.1 antibody-mediated complement lysis	8175
8 DIV , after which OECs grew to confluency -LRB- 2 -- 4 further DIV -RRB- before transplantation	8229
8 DIV	8229
OECs	8248
confluency -LRB- 2 -- 4 further DIV -RRB-	8261
confluency	8261
2 -- 4 further DIV	8273
2	8273
4 further DIV	8275
transplantation	8297
All cells for transplantation	8314
All cells	8314
transplantation	8328
48 hours	8356
surgery at 5,800 cells	8372
surgery	8372
5,800 cells	8383
cm2 in individual T25 or T75 flasks -LRB- Sigma , St. Louis , MO -RRB-	8396
cm2	8396
individual T25 or T75 flasks -LRB- Sigma , St. Louis , MO -RRB-	8403
individual T25 or T75 flasks	8403
Sigma	8433
St. Louis	8440
MO	8451
one flask of cells	8465
one flask	8465
cells	8478
transplantation	8512
each animal	8533
The total time from dissection to transplantation	8546
The total time	8546
dissection to transplantation	8566
dissection	8566
transplantation	8580
11	8608
14 DIV	8614
initial experiments by using freshly prepared LPOECs	8628
initial experiments	8628
freshly prepared LPOECs	8657
maintenance of phenotype	8691
maintenance	8691
phenotype	8706
cryopreservation of cells	8722
cryopreservation	8722
cells	8742
some experiments -LRB- 3 of 28-day rats , all 60-day rats , and all 28-day mice -RRB-	8749
some experiments	8749
3 of 28-day rats , all 60-day rats , and all 28-day mice	8767
3	8767
28-day rats , all 60-day rats , and all 28-day mice	8772
28-day rats	8772
all 60-day rats	8785
all 28-day mice	8806
OECs that were cryopreserved after 9 DIV -LRB- i.e. , 1 day after second Thy1 .1 antibody-mediated complement lysis -RRB-	8828
OECs	8828
9 DIV -LRB- i.e. , 1 day after second Thy1 .1 antibody-mediated complement lysis -RRB-	8863
9 DIV	8863
1	8876
day	8878
second Thy1 .1 antibody-mediated complement lysis	8888
second Thy1	8888
.1 antibody-mediated complement lysis	8899
Immunocytochemistry	8939
the second round of complement lysis	8965
the second round	8965
complement lysis	8985
a small aliquot of each culture	9003
a small aliquot	9003
each culture	9022
immunocytochemistry	9052
the purity of OECs used for grafting	9085
the purity	9085
OECs used for grafting	9099
OECs	9099
Primary antibodies used to test culture purity	9123
Primary antibodies	9123
culture purity	9155
anti- S100betta -LRB- 1:500 , Sigma -RRB- , low-affinity nerve growth factor receptor -LRB- p75 ; 1:500 , Chemicon , Temecula , CA -RRB- , and glial fibrillary acidic protein -LRB- GFAP ; 1:1000 , DakoCytomation , Denmark -RRB- overnight at 4 °C	9175
anti- S100betta -LRB- 1:500 , Sigma -RRB- , low-affinity nerve growth factor receptor -LRB- p75 ; 1:500 , Chemicon , Temecula , CA -RRB- , and glial fibrillary acidic protein -LRB- GFAP ; 1:1000 , DakoCytomation , Denmark -RRB- overnight	9175
anti- S100betta -LRB- 1:500 , Sigma -RRB- , low-affinity nerve growth factor receptor -LRB- p75 ; 1:500 , Chemicon , Temecula , CA -RRB- , and glial fibrillary acidic protein -LRB- GFAP ; 1:1000 , DakoCytomation , Denmark -RRB-	9175
anti- S100betta -LRB- 1:500 , Sigma -RRB-	9175
anti- S100betta	9175
1:500	9192
Sigma	9199
low-affinity nerve growth factor receptor -LRB- p75 ; 1:500 , Chemicon , Temecula , CA -RRB-	9207
low-affinity nerve growth factor receptor	9207
p75 ; 1:500	9250
p75	9250
1:500	9255
Chemicon , Temecula , CA	9262
Chemicon	9262
Temecula , CA	9272
glial fibrillary acidic protein -LRB- GFAP ; 1:1000 , DakoCytomation , Denmark -RRB-	9291
glial fibrillary acidic protein	9291
GFAP ; 1:1000	9324
GFAP	9324
1:1000	9330
DakoCytomation , Denmark	9338
DakoCytomation	9338
Denmark	9354
4 °C	9376
Cells	9381
secondary antibodies -LRB- 1:200 , Jackson ImmunoResearch , Mississauga , ON -RRB- raised in goat and conjugated to Alexa 594 for 1 hour at room temperature	9407
secondary antibodies	9407
1:200	9429
Jackson ImmunoResearch	9436
Mississauga , ON	9460
goat	9487
Alexa 594	9510
1 hour at room temperature	9524
1 hour	9524
room temperature	9534
Hoechst	9562
33258 -LRB- 1 µg/ml , Sigma -RRB- for 1 minute , and cover-slipped in glycerol mounting medium -LRB- Sigma -RRB-	9570
33258	9570
1 µg/ml	9577
Sigma	9586
1 minute	9597
cover-slipped in glycerol mounting medium -LRB- Sigma -RRB-	9611
cover-slipped	9611
glycerol mounting medium -LRB- Sigma -RRB-	9628
glycerol mounting medium	9628
Sigma	9654
Crush injury of the dorsolateral funiculus Male Sprague-Dawley rats -LRB- n = 33 , 150 -- 200 g , Charles River Breeding Laboratories -RRB- and male C57Bl/6 mice -LRB- n 12 , 25 -- 30 g , Charles River -RRB-	9662
Crush injury	9662
the dorsolateral funiculus Male Sprague-Dawley rats -LRB- n = 33 , 150 -- 200 g , Charles River Breeding Laboratories -RRB- and male C57Bl/6 mice -LRB- n 12 , 25 -- 30 g , Charles River -RRB-	9678
the dorsolateral funiculus Male Sprague-Dawley rats -LRB- n = 33 , 150 -- 200 g , Charles River Breeding Laboratories -RRB-	9678
the dorsolateral funiculus Male	9678
Sprague-Dawley rats -LRB- n = 33 , 150 -- 200 g , Charles River Breeding Laboratories -RRB-	9710
Sprague-Dawley rats	9710
n = 33 , 150 -- 200 g , Charles River Breeding Laboratories	9731
n	9731
= 33 , 150 -- 200 g , Charles River Breeding Laboratories	9733
= 33 , 150	9733
= 33	9733
150	9739
200 g , Charles River Breeding Laboratories	9743
200 g	9743
Charles River Breeding Laboratories	9750
male C57Bl/6 mice -LRB- n 12 , 25 -- 30 g , Charles River -RRB-	9791
male C57Bl/6 mice	9791
n 12 , 25 -- 30 g , Charles River	9810
n 12	9810
25 -- 30 g	9818
25	9818
30 g	9821
Charles River	9827
cyclosporin A -LRB- Novartis Pharmaceuticals , Mississauga , ON ; 10 mg/kg per day , i.p. -RRB-	9869
cyclosporin A	9869
Novartis Pharmaceuticals , Mississauga , ON ; 10 mg/kg per day , i.p.	9884
Novartis Pharmaceuticals , Mississauga , ON ; 10 mg/kg per day	9884
Novartis Pharmaceuticals , Mississauga , ON	9884
Novartis Pharmaceuticals	9884
Mississauga , ON	9910
10 mg/kg per day	9927
10 mg/kg	9927
day	9940
2 days	9962
injury and OEC transplantation	9976
survival	10038
All animal procedures	10048
accordance	10088
the guidelines of the Canadian Council for Animal Care	10104
the guidelines	10104
the Canadian Council for Animal Care	10122
the Canadian Council	10122
Animal Care	10147
our institution 's animal care committee	10175
our institution 's	10175
Animals	10216
ketamine -LRB- 70 mg/kg , i.p. -RRB- and xylazine -LRB- 10 mg/kg , i.p. -RRB-	10247
ketamine	10247
70 mg/kg , i.p.	10257
70 mg/kg	10257
xylazine	10277
10 mg/kg , i.p.	10287
10 mg/kg	10287
A hemilaminectomy	10304
the left half of the fourth cervical spinal cord segment -LRB- C4 -RRB-	10346
the left half	10346
the fourth cervical spinal cord segment -LRB- C4 -RRB-	10363
the fourth cervical spinal cord segment	10363
C4	10404
the dura	10413
microscissors	10435
Fine surgical forceps	10450
a depth of 1 mm	10489
a depth	10489
1 mm	10500
one prong at the border of the grey matter and one prong outside the dorsolateral funiculus : the forceps were closed and held for 18	10511
one prong at the border of the grey matter	10511
one prong	10511
the border of the grey matter	10524
the border	10524
the grey matter	10538
one prong outside the dorsolateral funiculus : the forceps were closed and held for 18	10558
one prong outside the dorsolateral funiculus	10558
one prong	10558
the dorsolateral funiculus	10576
the forceps	10604
18	10641
20 seconds	10644
the dorsolateral funiculus , including the rubrospinal tract	10664
the dorsolateral funiculus	10664
the rubrospinal tract	10702
completion of the injury	10730
completion	10730
the injury	10744
animals	10756
control	10803
an investigator other than the surgeon	10814
an investigator	10814
the surgeon	10841
OEC transplantation Immediately before transplantation , OECs were harvested in 0.25 % trypsin and 1 % ethylenediaminetetraacetic acid ,	10854
OEC transplantation	10854
transplantation	10893
OECs	10910
0.25 % trypsin and 1 % ethylenediaminetetraacetic acid	10933
0.25 % trypsin	10933
1 % ethylenediaminetetraacetic acid	10951
sterile phosphate buffered saline -LRB- PBS -RRB- , and resuspended in Dulbecco 's modified Eagles medium -LRB- DMEM -RRB- at 50,000 -- 100,000 OECs/µl	10997
sterile phosphate buffered saline -LRB- PBS -RRB- , and resuspended in Dulbecco 's	10997
sterile phosphate	10997
saline -LRB- PBS -RRB-	11024
saline	11024
PBS	11032
Dulbecco 's	11057
Eagles medium -LRB- DMEM -RRB-	11077
Eagles	11077
DMEM	11092
50,000	11101
100,000 OECs/µl	11108
the crush injury	11140
75,000 -- 150,000 OECs -LRB- 1.5 µl of cell slurry for rats , 1 µl of cell slurry for mice , divided over three injection sites -RRB-	11158
75,000 -- 150,000 OECs	11158
75,000	11158
150,000 OECs	11165
1.5 µl of cell slurry for rats , 1 µl of cell slurry for mice , divided over three injection sites	11179
1.5 µl	11179
cell slurry for rats , 1 µl of cell slurry for mice ,	11189
cell slurry	11189
rats , 1 µl of cell slurry for mice ,	11205
rats	11205
1 µl of cell slurry for mice	11211
1 µl	11211
cell slurry for mice	11219
cell slurry	11219
mice	11235
three injection sites	11254
the lesion site	11317
a pulled glass pipette -LRB- tip diameter = 20 µm -RRB- glued to a Hamilton syringe	11342
a pulled glass pipette -LRB- tip diameter = 20 µm -RRB-	11342
a pulled glass pipette	11342
tip diameter = 20 µm	11366
tip diameter =	11366
tip	11366
20 µm	11381
a Hamilton syringe	11397
The cell slurry	11417
a rate of 100 nl/min	11451
a rate	11451
100 nl/min	11461
the pipette	11477
place for 5 minutes	11501
place	11501
5 minutes	11511
each injection	11527
Control animals	11543
identical volumes of DMEM	11568
identical volumes	11568
DMEM	11589
the same rate and sites	11606
the same rate	11606
sites	11624
the final injection	11637
the pipette	11658
the muscle and skin	11695
interrupted sutures	11732
Survival times	11753
48 hours -LRB- n = 6 -RRB- , 7 days -LRB- n = 6 -RRB- , 28 days -LRB- n = 15 -RRB- , and 60 days -LRB- n = 6 -RRB- for rats and 28 days -LRB- n = 12 -RRB- for mice	11773
48 hours -LRB- n = 6 -RRB- , 7 days -LRB- n = 6 -RRB- , 28 days -LRB- n = 15 -RRB- , and 60 days -LRB- n = 6 -RRB- for rats	11773
48 hours -LRB- n = 6 -RRB-	11773
n	11783
6	11787
7 days -LRB- n = 6 -RRB-	11791
n	11799
6	11803
28 days -LRB- n = 15 -RRB-	11807
n	11816
15	11820
60 days -LRB- n = 6 -RRB- for rats	11829
60 days -LRB- n = 6 -RRB-	11829
n	11838
6	11842
rats	11849
28 days -LRB- n = 12 -RRB- for mice	11858
28 days -LRB- n = 12 -RRB-	11858
n	11867
12	11871
mice	11879
Anterograde labeling of rubrospinal axons One week before the end of the survival period	11885
Anterograde labeling	11885
rubrospinal axons One week before the end of the survival period	11909
rubrospinal axons	11909
One week	11927
the end of the survival period	11943
the end	11943
the survival period	11954
animals	11975
a Kopf stereotaxic frame	12012
dextran amine -LRB- BDA ; 10,000 kDa molecular mass , 25 % in 0.5 % dimethylsulfoxide , Molecular Probes , Eugene , OR -RRB-	12055
dextran amine	12055
BDA ; 10,000 kDa molecular mass , 25 % in 0.5 % dimethylsulfoxide , Molecular Probes , Eugene , OR	12070
BDA ; 10,000 kDa molecular mass	12070
BDA	12070
10,000 kDa molecular mass	12075
10,000 kDa	12075
molecular mass	12086
25 % in 0.5 % dimethylsulfoxide	12102
25 %	12102
0.5 % dimethylsulfoxide	12109
Molecular Probes	12133
Eugene , OR	12151
Eugene	12151
OR	12159
the red nucleus	12197
a rate of 80 nl/min	12216
a rate	12216
80 nl/min	12226
5.9 mm caudal to bregma , 0.7 mm lateral to midline , and 7 mm deep	12259
5.9 mm caudal	12259
bregma	12276
0.7 mm lateral to midline	12284
0.7 mm lateral	12284
midline	12302
7 mm	12315
Total injection volume	12326
animal size	12361
0.5 -- 0.8 µl	12378
0.5	12378
0.8 µl	12382
the pipette	12394
place for 5 minutes	12418
place	12418
5 minutes	12428
injection	12444
Immunohistochemistry At the end of the survival period , animals were killed with an overdose of chloral hydrate -LRB- 100 mg/kg , i.p. -RRB- and perfused transcardially with PBS	12455
Immunohistochemistry	12455
the end of the survival period	12479
the end	12479
the survival period	12490
animals	12511
an overdose of chloral hydrate -LRB- 100 mg/kg , i.p. -RRB-	12536
an overdose	12536
chloral hydrate -LRB- 100 mg/kg , i.p. -RRB-	12551
chloral hydrate	12551
100 mg/kg , i.p.	12568
100 mg/kg	12568
PBS	12618
phosphate buffered , 4 % paraformaldehyde -LRB- pH 7.4 -RRB-	12634
phosphate buffered	12634
phosphate	12634
4 % paraformaldehyde -LRB- pH 7.4 -RRB-	12654
4 % paraformaldehyde	12654
pH 7.4	12675
The cervical spinal cords	12684
4 % paraformaldehyde	12740
overnight ; cryoprotected in 12 % , 18 % , and 22 % sucrose in 0.1 M phosphate buffer over 3 days ;	12760
overnight	12760
12 % , 18 % , and 22 % sucrose in 0.1 M phosphate buffer over 3 days	12788
12 %	12788
18 %	12793
22 % sucrose in 0.1 M phosphate buffer over 3 days	12802
22 % sucrose	12802
0.1 M phosphate buffer over 3 days	12817
0.1 M phosphate buffer	12817
3 days	12845
isopentane over dry ice	12867
isopentane	12867
dry ice	12883
Cervical segments from C2 to C6	12892
Cervical segments	12892
C2 to C6	12915
C2	12915
C6	12921
20-micron longitudinal sections in the horizontal plane on a cryostat	12938
20-micron longitudinal sections	12938
the horizontal plane on a cryostat	12973
the horizontal plane	12973
a cryostat	12997
-80 °C	13022
Frozen sections	13029
a slide warmer for 5 minutes	13060
a slide warmer	13060
5 minutes	13079
PBS , permeabilized for 1 hour in 0.1 % Triton-X 100 ,	13104
PBS	13104
1 hour in 0.1 % Triton-X	13127
1 hour	13127
0.1 % Triton-X	13137
100	13151
10 % goat serum for 20 minutes	13175
10 % goat serum	13175
20 minutes	13194
nonspecific binding	13216
The following primary antibodies	13237
rabbit anti-GFP -LRB- 1:1000 , Abcam , Cambridge , UK -RRB- , rabbit anti-p75 -LRB- 1:500 , Chemicon -RRB- , mouse anti-rat endothelial cell antigen -LRB- anti -- RECA-1 ; Serotec -RRB- , mouse anti-rat p75 -LRB- 1:50 , Boehringer-Mannheim , Mannheim , Germany -RRB- , rabbit anti-GFAP -LRB- 1:1,000 , Dako -RRB- , mouse anti-neurofilament -LRB- anti-NF200 , 1:500 , Sigma -RRB- , mouse anti- III tubulin -LRB- TuJ1 ; 1:500 , Sigma -RRB- , mouse anti- CSPG -LRB- 1:20 , Sigma -RRB- , rabbit anti-serotonin -LRB- anti-5HT , 1:8000 , ImmunoStar , Hudson , WI -RRB- , sheep anti-tyrosine hydroxylase -LRB- anti-TH , 1:500 , Chemicon -RRB- , rabbit anti-p200 -LRB- gift of Dr. David Carey , Penn State School of medicine -RRB- , and rabbit anti-calcitonin gene-related peptide -LRB- anti- CGRP , 1:4,000 , Sigma -RRB-	13281
rabbit anti-GFP -LRB- 1:1000 , Abcam , Cambridge , UK -RRB- , rabbit anti-p75 -LRB- 1:500 , Chemicon -RRB- , mouse anti-rat endothelial cell antigen -LRB- anti -- RECA-1 ; Serotec -RRB- , mouse anti-rat p75 -LRB- 1:50 , Boehringer-Mannheim , Mannheim , Germany -RRB- , rabbit anti-GFAP -LRB- 1:1,000 , Dako -RRB- , mouse anti-neurofilament -LRB- anti-NF200 , 1:500 , Sigma -RRB- , mouse anti- III tubulin -LRB- TuJ1 ; 1:500 , Sigma -RRB- , mouse anti- CSPG -LRB- 1:20 , Sigma -RRB- , rabbit anti-serotonin -LRB- anti-5HT , 1:8000 , ImmunoStar , Hudson , WI -RRB- , sheep anti-tyrosine hydroxylase -LRB- anti-TH , 1:500 , Chemicon -RRB- , rabbit anti-p200 -LRB- gift of Dr. David Carey , Penn State School of medicine -RRB- , and rabbit anti-calcitonin gene-related peptide	13281
rabbit anti-GFP -LRB- 1:1000 , Abcam , Cambridge , UK -RRB-	13281
rabbit anti-GFP	13281
1:1000	13298
Abcam	13306
Cambridge , UK	13313
rabbit anti-p75 -LRB- 1:500 , Chemicon -RRB-	13329
rabbit anti-p75	13329
1:500	13346
Chemicon	13353
mouse anti-rat endothelial cell antigen -LRB- anti -- RECA-1 ; Serotec -RRB- , mouse anti-rat p75 -LRB- 1:50 , Boehringer-Mannheim , Mannheim , Germany -RRB- , rabbit anti-GFAP -LRB- 1:1,000 , Dako -RRB- , mouse anti-neurofilament -LRB- anti-NF200 , 1:500 , Sigma -RRB- , mouse anti- III tubulin -LRB- TuJ1 ; 1:500 , Sigma -RRB- , mouse anti- CSPG -LRB- 1:20 , Sigma -RRB- , rabbit anti-serotonin -LRB- anti-5HT , 1:8000 , ImmunoStar , Hudson , WI -RRB- , sheep anti-tyrosine hydroxylase -LRB- anti-TH , 1:500 , Chemicon -RRB- , rabbit anti-p200 -LRB- gift of Dr. David Carey , Penn State School of medicine -RRB-	13364
mouse anti-rat endothelial cell antigen -LRB- anti -- RECA-1 ; Serotec -RRB-	13364
mouse anti-rat endothelial cell antigen	13364
anti	13405
RECA-1 ; Serotec	13410
RECA-1	13410
Serotec	13418
mouse anti-rat p75 -LRB- 1:50 , Boehringer-Mannheim , Mannheim , Germany -RRB-	13428
mouse anti-rat p75	13428
1:50	13448
Boehringer-Mannheim	13454
Mannheim , Germany	13475
rabbit anti-GFAP -LRB- 1:1,000 , Dako -RRB-	13495
rabbit anti-GFAP	13495
1:1,000	13513
Dako	13522
mouse anti-neurofilament -LRB- anti-NF200 , 1:500 , Sigma -RRB-	13529
mouse anti-neurofilament	13529
anti-NF200	13555
1:500	13567
Sigma	13574
mouse anti- III tubulin -LRB- TuJ1 ; 1:500 , Sigma -RRB-	13582
mouse anti- III tubulin	13582
mouse	13582
anti- III tubulin	13588
III	13594
TuJ1 ; 1:500 , Sigma	13607
TuJ1	13607
1:500 , Sigma	13612
1:500	13612
Sigma	13619
mouse anti- CSPG -LRB- 1:20 , Sigma -RRB-	13627
mouse anti- CSPG	13627
1:20	13645
Sigma	13651
rabbit anti-serotonin -LRB- anti-5HT , 1:8000 , ImmunoStar , Hudson , WI -RRB-	13659
rabbit anti-serotonin	13659
anti-5HT , 1:8000 , ImmunoStar , Hudson , WI	13682
anti-5HT	13682
1:8000	13692
ImmunoStar	13700
Hudson	13712
WI	13720
sheep anti-tyrosine hydroxylase -LRB- anti-TH , 1:500 , Chemicon -RRB-	13725
sheep anti-tyrosine hydroxylase	13725
anti-TH	13758
1:500	13767
Chemicon	13774
rabbit anti-p200 -LRB- gift of Dr. David Carey , Penn State School of medicine -RRB-	13785
rabbit anti-p200	13785
gift of Dr. David Carey , Penn State School of medicine	13803
gift	13803
Dr. David Carey , Penn State School of medicine	13811
Dr. David Carey	13811
Penn State School of medicine	13828
Penn State School	13828
medicine	13849
rabbit anti-calcitonin gene-related peptide	13864
anti- CGRP	13909
1:4,000	13921
Sigma	13930
All primary antibodies	13938
4 °C	13987
Secondary antibodies -LRB- 1:200 , Jackson -RRB- raised in goat or donkey and conjugated to Alexa 594 , Alexa 488 , Alexa 350 , Cy3 , or aminomethylcoumarin -LRB- AMCA -RRB-	13992
Secondary antibodies -LRB- 1:200 , Jackson -RRB- raised in goat or donkey and conjugated to Alexa 594 , Alexa 488 , Alexa 350 , Cy3 , or aminomethylcoumarin	13992
Secondary antibodies -LRB- 1:200 , Jackson -RRB-	13992
Secondary antibodies	13992
1:200	14014
Jackson	14021
goat or donkey	14040
Alexa 594 , Alexa 488 , Alexa 350 , Cy3 , or aminomethylcoumarin	14073
Alexa 594	14073
Alexa 488	14084
Alexa 350	14095
Cy3	14106
aminomethylcoumarin	14114
AMCA	14135
1 hour at room temperature	14158
1 hour	14158
room temperature	14168
BDA	14186
Cy3 - or AMCA-conjugated streptavidin -LRB- 1:200 , Jackson -RRB- applied for 1 hour at room temperature	14214
Cy3	14214
AMCA-conjugated streptavidin -LRB- 1:200 , Jackson -RRB- applied for 1 hour at room temperature	14222
AMCA-conjugated streptavidin -LRB- 1:200 , Jackson -RRB-	14222
AMCA-conjugated streptavidin	14222
1:200	14252
Jackson	14259
1 hour at room temperature	14280
1 hour	14280
room temperature	14290
Sections	14308
glycerol mounting medium -LRB- Sigma -RRB- or Vectashield -LRB- Vector Laboratories , Burlingame , CA -RRB-	14339
glycerol mounting medium -LRB- Sigma -RRB-	14339
glycerol mounting medium	14339
Sigma	14365
Vectashield -LRB- Vector Laboratories , Burlingame , CA -RRB-	14375
Vectashield	14375
Vector Laboratories	14388
Burlingame	14409
CA	14421
Image analysis and quantification Digital images	14426
Image analysis	14426
quantification Digital images	14445
an Axioplan 2 microscope -LRB- Zeiss , Jena , Germany -RRB- , a digital camera -LRB- QImaging , Burnaby , BC , Canada -RRB- , and Northern Eclipse software -LRB- Empix Imaging , Inc. , Mississauga , ON , Canada -RRB-	14494
an Axioplan 2 microscope -LRB- Zeiss , Jena , Germany -RRB-	14494
an Axioplan 2 microscope	14494
Zeiss	14520
Jena	14527
Germany	14533
a digital camera -LRB- QImaging , Burnaby , BC , Canada -RRB-	14543
a digital camera	14543
QImaging	14561
Burnaby	14571
BC , Canada	14580
Northern Eclipse software -LRB- Empix Imaging , Inc. , Mississauga , ON , Canada -RRB-	14597
Northern Eclipse software	14597
Empix Imaging	14624
Inc. , Mississauga	14639
ON , Canada	14658
Northern Eclipse and SigmaScan Pro -LRB- SPSS Inc. , Chicago , IL -RRB-	14698
Northern Eclipse	14698
SigmaScan Pro -LRB- SPSS Inc. , Chicago , IL -RRB-	14719
SigmaScan	14719
Pro -LRB- SPSS Inc. , Chicago , IL -RRB-	14729
Pro	14729
SPSS Inc.	14734
Chicago	14745
IL	14754
software	14758
Cavity size	14768
the area of cavity in 10 serial horizontal sections per animal	14808
the area	14808
cavity in 10 serial horizontal sections per animal	14820
cavity	14820
10 serial horizontal sections per animal	14830
10 serial horizontal sections	14830
animal	14864
a section-to-section interval of 100 µm	14876
a section-to-section interval	14876
100 µm	14909
the dorsal surface of the spinal cord	14928
the dorsal surface	14928
the spinal cord	14950
These 10 measurements	14967
the cumulative area of each animal	15011
the cumulative area	15011
each animal	15034
a relative measure of the lesion size	15049
a relative measure	15049
the lesion size	15071
A Student 's t test	15088
A Student 's	15088
treatment groups	15127
Rostral -- caudal migration of OECs was measured as the shortest distance of each GFPpositive object -LRB- cell or group of cells -RRB- from a line drawn perpendicular to the dorsal columns , through the lesion epicenter .	15145
Rostral	15145
caudal migration of OECs	15153
caudal migration	15153
OECs	15173
the shortest distance of each GFPpositive object -LRB- cell or group of cells -RRB-	15194
the shortest distance	15194
each GFPpositive object -LRB- cell or group of cells -RRB-	15219
each GFPpositive object	15219
cell or group of cells	15244
cell or group	15244
cells	15261
a line drawn perpendicular to the dorsal columns , through the lesion epicenter	15273
a line	15273
the dorsal columns	15303
the lesion epicenter	15331
Measurements of rostral and caudal migration -LRB- on either side of the injection site -RRB-	15353
Measurements	15353
rostral and caudal migration -LRB- on either side of the injection site -RRB-	15369
rostral and caudal migration	15369
either side of the injection site	15402
either side	15402
the injection site	15417
each time point	15476
cells in the pia mater	15493
cells	15493
the pia mater	15502
Measurements	15531
100 images of three-to-five longitudinal sections per animal	15560
100 images	15560
three-to-five longitudinal sections per animal	15575
three-to-five longitudinal sections	15575
animal	15615
RESULTS	15624
1	15637
Lamina propria olfactory ensheathing cells -LRB- LP-OECs -RRB-	15640
Lamina propria olfactory ensheathing cells	15640
Lamina propria	15640
olfactory ensheathing cells	15655
LP-OECs	15684
cavitation	15701
limited survival and migration	15721
rat spinal cord	15755
a , c , e , g : In horizontal sections of spinal cord from control rats , a cavity formed at the injury site as early as 2 days after dorsolateral funiculus crush , reaching maximal volumes at 28 days after lesion -LRB- n = 6 -RRB- .	15772
a	15772
c , e	15774
c	15774
g : In horizontal sections of spinal cord from control rats , a cavity formed at the injury site as early as 2 days after dorsolateral funiculus crush	15778
g : In horizontal sections of spinal cord	15778
g	15778
horizontal sections of spinal cord	15784
horizontal sections	15784
spinal cord	15807
control rats , a cavity formed at the injury site as early as 2 days after dorsolateral funiculus crush	15824
control rats	15824
a cavity formed at the injury site as early as 2 days after dorsolateral funiculus crush	15838
a cavity	15838
the injury site as early as 2 days	15857
the injury site	15857
2 days	15885
dorsolateral funiculus crush	15898
maximal volumes	15937
28 days after lesion -LRB- n = 6 -RRB-	15956
28 days	15956
lesion -LRB- n = 6 -RRB-	15970
lesion	15970
n	15978
6	15982
f , h : Cavities	15990
f	15990
h : Cavities	15992
h	15992
Cavities	15995
animals that received a transplant of green fluorescent protein -LRB- GFP -RRB- - positive LP-OECs into the site of injury -LRB- n 9 -RRB-	16023
animals that received a transplant of green fluorescent protein -LRB- GFP -RRB-	16023
animals	16023
a transplant of green fluorescent protein	16045
a transplant	16045
green fluorescent protein	16061
GFP	16088
positive LP-OECs into the site of injury -LRB- n 9 -RRB-	16094
positive LP-OECs	16094
the site of injury -LRB- n 9 -RRB-	16116
the site	16116
injury -LRB- n 9 -RRB-	16128
injury	16128
n 9	16136
The number of transplanted LP-OECs	16144
The number	16144
transplanted LP-OECs	16158
2 to 60 days	16202
GFP-positive OECs	16220
five of nine animals 28 days	16255
five	16255
nine animals	16263
28 days	16276
transplantation and zero of three animals 60 days	16290
transplantation	16290
zero of three animals 60 days	16310
zero	16310
three animals 60 days	16318
three animals	16318
60 days	16332
transplantation	16346
Autofluorescent macrophages -LRB- arrowheads -RRB- infiltrated into the lesion site area in both medium - and OEC-injected animals after 7 days after lesion and from 28 to 60 days	16363
Autofluorescent macrophages -LRB- arrowheads -RRB-	16363
Autofluorescent macrophages	16363
arrowheads	16392
the lesion site area	16421
medium - and OEC-injected animals	16450
7 days after lesion	16489
7 days	16489
lesion	16502
28 to 60 days	16518
several segments rostral and caudal	16543
several segments	16543
the lesion	16582
i	16594
Migration of GFP-positive cells	16597
Migration	16597
GFP-positive cells	16610
the center of the injection site	16670
the center	16670
the injection site	16684
white arrow	16704
lesion center	16727
b , used as zero for measurements	16744
b	16744
zero	16755
measurements	16764
time -LRB- 2 days -LSB- d -RSB- : n = 3 ; 7 d : n = 3 ; 28 d : n = 3 -RRB-	16813
time	16813
2 days -LSB- d -RSB- : n = 3 ; 7 d : n = 3 ; 28 d : n = 3	16819
2 days	16819
d -RSB- : n = 3 ; 7 d : n = 3 ; 28 d : n	16827
d -RSB-	16827
n = 3	16831
n	16831
3	16835
7 d	16838
n = 3	16843
n	16843
3	16847
28 d	16850
n	16856
3	16860
Scale	16864
= 400 µm in a -LRB- applies to a -- h -RRB-	16874
= 400 µm	16874
400	16876
a	16886
a -- h	16900
h	16902
Fig. 2 .	16907
Fig.	16907
2	16912
Lamina propria olfactory ensheathing cell -LRB- LP-OEC -RRB- transplantation	16915
Lamina propria	16915
olfactory ensheathing cell -LRB- LP-OEC -RRB- transplantation	16930
Schwann cell invasion	16994
the lesion site	17021
a	17038
early as 7 days after LP-OEC transplantation -LRB- green fluorescent protein -LSB- GFP -RSB- , green -RRB-	17044
early as 7 days after LP-OEC transplantation	17044
7 days after LP-OEC	17053
7 days	17053
LP-OEC	17066
green fluorescent protein -LSB- GFP -RSB- , green	17090
green fluorescent protein	17090
GFP	17117
host Schwann cells expressing a rat-specific form of p75 -LRB- red -RRB-	17131
host Schwann cells	17131
a rat-specific form of p75 -LRB- red -RRB-	17161
a rat-specific form	17161
p75 -LRB- red -RRB-	17184
p75	17184
red	17189
the core of the lesion site , which was surrounded by glial fibrillary acidic protein -LRB- GFAP -RRB- - positive -LRB- blue -RRB- astrocytes	17213
the core	17213
the lesion site , which was surrounded by glial fibrillary acidic protein -LRB- GFAP -RRB- - positive -LRB- blue -RRB- astrocytes	17225
the lesion site	17225
glial fibrillary acidic protein -LRB- GFAP -RRB-	17266
glial fibrillary acidic protein	17266
GFAP	17299
positive -LRB- blue -RRB- astrocytes	17306
b : By 28 days after transplantation , surviving GFPpositive LP-OECs -LRB- green ; n = 5 of 9 -RRB-	17334
b : By 28 days	17334
b	17334
28 days	17340
transplantation , surviving GFPpositive LP-OECs -LRB- green ; n = 5 of 9 -RRB-	17354
transplantation	17354
surviving GFPpositive LP-OECs -LRB- green ; n = 5 of 9 -RRB-	17371
surviving GFPpositive LP-OECs	17371
green ; n = 5 of 9	17402
green	17402
n = 5 of 9	17409
n = 5	17409
n	17409
5	17413
9	17418
the core of the lesion , where p75-positive Schwann cells -LRB- red -RRB- migrated out to interface with GFAP-positive -LRB- blue -RRB- astrocytes at the lesion boundary	17438
the core	17438
the lesion , where p75-positive Schwann cells -LRB- red -RRB- migrated out to interface with GFAP-positive -LRB- blue -RRB- astrocytes at the lesion boundary	17450
the lesion	17450
p75-positive Schwann cells -LRB- red -RRB-	17468
p75-positive Schwann cells	17468
red	17496
interface	17517
GFAP-positive -LRB- blue -RRB- astrocytes	17532
the lesion boundary	17567
c	17588
control rats at 28 days after lesion	17594
control rats	17594
28 days after lesion	17610
28 days	17610
lesion	17624
a few host Schwann cells	17632
the lateral aspect of the lesion site -LRB- arrow -RRB- adjacent to the GFAP-positive -LRB- blue -RRB- scar border of the cavity -LRB- n = 6 -RRB-	17674
the lateral aspect	17674
the lesion site -LRB- arrow -RRB- adjacent to the GFAP-positive -LRB- blue -RRB- scar border of the cavity -LRB- n = 6 -RRB-	17696
the lesion site -LRB- arrow -RRB- adjacent to the GFAP-positive -LRB- blue -RRB- scar border of the cavity	17696
the lesion site -LRB- arrow -RRB-	17696
the lesion site	17696
arrow	17713
the GFAP-positive -LRB- blue -RRB- scar border of the cavity	17732
the GFAP-positive -LRB- blue -RRB- scar border	17732
the cavity	17772
n	17784
6	17788
d	17792
contrast , 28 days after LP-OEC transplantation	17798
contrast	17798
28 days after LP-OEC transplantation	17808
28 days	17808
LP-OEC transplantation	17822
the lesion site	17846
host p75-positive Schwann cells -LRB- red -RRB- , accompanied by autofluorescent immune infiltrates -LRB- yellow ; n = 6 -RRB-	17889
host p75-positive Schwann cells -LRB- red -RRB-	17889
host	17889
p75-positive Schwann cells -LRB- red -RRB-	17894
p75-positive Schwann cells	17894
red	17922
autofluorescent immune infiltrates -LRB- yellow ; n = 6 -RRB-	17943
autofluorescent immune infiltrates	17943
yellow ; n = 6	17979
yellow	17979
n = 6	17987
n	17987
6	17991
Rat p75-positive Schwann cells persisted at the lesion site 60 days , at which time LP-OECs could no longer be detected -LRB- n = 3 -RRB-	17998
Rat	17998
p75-positive Schwann cells	18002
the lesion site	18042
60 days	18058
time LP-OECs	18076
n = 3	18118
n	18118
= 3	18120
28 days , significant laminin deposition -LRB- blue -RRB-	18132
28 days	18132
significant laminin deposition -LRB- blue -RRB-	18141
significant laminin deposition	18141
blue	18173
the lesion boundary	18196
a penumbra similar to that demarcated by earlier LP-OEC migration routes	18220
a penumbra	18220
that demarcated by earlier LP-OEC migration routes	18242
that	18242
earlier LP-OEC migration routes	18261
g : At higher power -LRB- from boxed area in f -RRB- , the p75-positive Schwann cell migration route -LRB- red -RRB- is closely associated with regions of high laminin deposition -LRB- arrowhead ; blue -RRB- and punctate immune infiltration -LRB- red ; white asterisks -RRB- can also be seen .	18294
g	18294
higher power -LRB- from boxed area in f -RRB- , the p75-positive Schwann cell migration route -LRB- red -RRB- is closely associated with regions of high laminin deposition -LRB- arrowhead ; blue -RRB- and punctate immune infiltration -LRB- red ; white asterisks -RRB-	18300
higher power	18300
area	18325
f -RRB- , the p75-positive Schwann cell migration route -LRB- red -RRB- is closely associated with regions of high laminin deposition -LRB- arrowhead ; blue -RRB- and punctate immune infiltration -LRB- red ; white asterisks	18333
f -RRB- , the p75-positive Schwann cell migration route -LRB- red -RRB- is closely associated with regions of high laminin deposition -LRB- arrowhead ; blue -RRB-	18333
the p75-positive Schwann cell migration route -LRB- red -RRB- is closely associated with regions of high laminin deposition -LRB- arrowhead ; blue -RRB-	18337
the p75-positive Schwann cell migration route	18337
red	18384
regions of high laminin deposition -LRB- arrowhead ; blue -RRB-	18416
regions	18416
high laminin deposition -LRB- arrowhead ; blue -RRB-	18427
high laminin deposition	18427
arrowhead ; blue	18452
arrowhead	18452
blue	18463
punctate immune infiltration -LRB- red ; white asterisks	18473
punctate immune infiltration	18473
red ; white asterisks	18503
red	18503
white asterisks	18508
h : GFAP-positive astrocytes -LRB- red -RRB- form linear arrays around the lesion site outside the laminin -LRB- blue -RRB- boundary encasing both GFP-positive LP-OECs and endogenous Schwann cells .	18543
h	18543
GFAP-positive astrocytes -LRB- red -RRB- form linear arrays around the lesion site outside the laminin -LRB- blue -RRB- boundary encasing both GFP-positive LP-OECs and endogenous Schwann cells	18546
GFAP-positive astrocytes	18546
red	18572
linear arrays around the lesion site outside the laminin -LRB- blue -RRB- boundary	18582
linear arrays	18582
the lesion site outside the laminin -LRB- blue -RRB- boundary	18603
the lesion site	18603
the laminin -LRB- blue -RRB- boundary	18627
blue	18640
both GFP-positive LP-OECs and endogenous Schwann cells	18664
GFP-positive LP-OECs	18669
endogenous Schwann cells	18694
i : The close boundaries formed between GFAP-positive astrocytes -LRB- red -RRB- and laminin -LRB- blue -RRB- at the lesion boundary can be appreciated better at higher power -LRB- from boxed area in h -RRB- .	18720
i	18720
The close boundaries	18723
GFAP-positive astrocytes -LRB- red -RRB-	18759
GFAP-positive astrocytes	18759
red	18785
laminin -LRB- blue -RRB- at the lesion boundary	18794
laminin -LRB- blue -RRB-	18794
laminin	18794
blue	18803
the lesion boundary	18812
higher power -LRB- from boxed area in h -RRB-	18861
higher power	18861
boxed area in h	18880
boxed area	18880
h	18894
Scale bars = 100 µm in a , b , g , i ; 200 µm in c -- f , h. Fig. 3 .	18898
Scale bars	18898
100 µm in a , b , g , i	18911
100 µm in a	18911
100 µm	18911
a	18921
b	18923
g	18925
200 µm in c -- f , h. Fig. 3	18930
200 µm in c	18930
200 µm	18930
c	18940
f , h. Fig. 3	18942
h. Fig. 3	18944
h. Fig.	18944
3	18953
Glial scar formation	18956
lamina propria olfactory ensheathing cell -LRB- LP-OEC -RRB- transplantation	18994
lamina propria	18994
olfactory ensheathing cell -LRB- LP-OEC -RRB- transplantation	19009
olfactory ensheathing cell	19009
LP-OEC	19037
transplantation	19045
a , b : Twenty-eight days after lesion , the formation of a glial scar in control animals is demonstrated by the dense accumulation of glial fibrillary acidic protein -LRB- GFAP -RRB- - positive astrocytes -LRB- red ; arrow -RRB- and localized deposition of successive parallel barriers of chondroitin sulfate proteoglycan -LRB- CSPG ; green ; arrowheads -RRB- at the edge of the lesion cavity .	19062
a	19062
b	19064
Twenty-eight days after lesion	19067
Twenty-eight days	19067
lesion	19091
the formation of a glial scar in control animals	19099
the formation	19099
a glial scar in control animals	19116
a glial scar	19116
control animals	19132
the dense accumulation of glial fibrillary acidic protein -LRB- GFAP -RRB- - positive astrocytes -LRB- red ; arrow -RRB- and localized deposition of successive parallel barriers of chondroitin sulfate proteoglycan -LRB- CSPG ; green ; arrowheads -RRB-	19167
the dense accumulation	19167
glial fibrillary acidic protein -LRB- GFAP -RRB- - positive astrocytes -LRB- red ; arrow -RRB- and localized deposition	19193
glial fibrillary acidic protein -LRB- GFAP -RRB-	19193
glial fibrillary acidic protein	19193
GFAP	19226
positive astrocytes -LRB- red ; arrow -RRB-	19233
positive astrocytes	19233
red ; arrow	19254
red	19254
arrow	19259
localized deposition	19270
successive parallel barriers of chondroitin sulfate proteoglycan -LRB- CSPG ; green ; arrowheads -RRB-	19294
successive parallel barriers	19294
chondroitin sulfate proteoglycan -LRB- CSPG ; green ; arrowheads -RRB-	19326
chondroitin sulfate proteoglycan	19326
CSPG	19360
green ; arrowheads	19366
green	19366
arrowheads	19373
the edge of the lesion cavity	19388
the edge	19388
the lesion cavity	19400
c	19419
addition to the absence of a cavity	19425
addition	19425
the absence of a cavity	19437
the absence	19437
a cavity	19452
animals that received LP-OEC transplants	19462
animals	19462
LP-OEC transplants	19484
GFAP-positive astrocytes -LRB- red -RRB- and CSPG deposition -LRB- green -RRB- in a diffuse linear array distant	19511
GFAP-positive astrocytes	19511
red	19537
CSPG deposition -LRB- green -RRB- in a diffuse linear array distant	19546
CSPG deposition -LRB- green -RRB-	19546
CSPG deposition	19546
a diffuse linear array distant	19573
the lesion site center -LRB- asterisk -RRB-	19609
the lesion site center	19609
asterisk	19633
d	19644
the lesion boundary -LRB- from boxed area in c -RRB-	19650
the lesion boundary	19650
area in c	19682
area	19682
c	19690
CSPG deposition -LRB- red -RRB-	19694
CSPG deposition	19694
red	19711
more	19723
GFAP-rich astrocyte-lined channels -LRB- arrowhead -RRB-	19748
GFAP-rich astrocyte-lined channels	19748
arrowhead	19784
f : The rearrangement of endogenous glia at the lesion boundary ,	19798
f	19798
The rearrangement of endogenous glia	19801
The rearrangement	19801
endogenous glia	19822
the lesion boundary	19841
profuse in-growth of neurofilament 200 -LRB- NF200 -RRB- - positive axons -LRB- blue -RRB- through radiating GFAP-positive astrocytes -LRB- red ; asterisks -RRB- into the Schwann cell-rich lesion site	19870
profuse in-growth of neurofilament 200 -LRB- NF200 -RRB-	19870
profuse in-growth	19870
neurofilament 200 -LRB- NF200 -RRB-	19891
positive axons -LRB- blue -RRB- through radiating GFAP-positive astrocytes -LRB- red ; asterisks -RRB- into the Schwann cell-rich lesion site	19918
positive axons -LRB- blue -RRB-	19918
positive axons	19918
blue	19934
GFAP-positive astrocytes -LRB- red ; asterisks -RRB-	19958
GFAP-positive astrocytes	19958
red ; asterisks	19984
red	19984
asterisks	19989
the Schwann cell-rich lesion site	20005
Scale bars	20040
200 µm in a , c , e ; 50 µm in b , d , f. Fig. 4	20053
200 µm in a , c , e	20053
200 µm	20053
a , c ,	20063
a	20063
c	20065
50 µm in b , d , f. Fig. 4	20070
50 µm in b , d , f. Fig.	20070
50 µm	20070
b , d , f. Fig.	20079
4	20092
Multiple axonal populations	20095
the olfactory ensheathing cell -LRB- OEC -RRB-	20146
the olfactory ensheathing cell	20146
OEC	20178
transplanted spinal cord lesion site	20184
transplanted spinal cord lesion	20184
site	20216
a	20222
control animals , 60 days after lesion	20228
control animals	20228
60 days after lesion	20245
60 days	20245
lesion	20259
axons	20267
the wall of the cavity	20284
the wall	20284
the cavity	20296
the lateral aspect of the lesion -LRB- n 3 -RRB-	20324
the lateral aspect	20324
the lesion -LRB- n 3 -RRB-	20346
the lesion	20346
n 3	20358
This pattern	20366
all tracts examined in control animals	20394
all tracts	20394
control animals	20417
b -- e : Sixty days	20434
b	20434
Sixty	20439
OEC injection	20456
no OECs	20480
the lesion site	20502
there	20519
massive growth of axons into and in some instances across the lesion site into the distal cord -LRB- arrows -RRB- the expressed -LRB- b , c -RRB-	20529
massive growth	20529
axons into and in some instances across the lesion site into the distal cord -LRB- arrows -RRB- the expressed	20547
axons into and in some instances across the lesion site into the distal cord -LRB- arrows -RRB- the	20547
axons	20547
some instances across the lesion site	20565
some instances	20565
the lesion site	20587
the distal cord -LRB- arrows -RRB-	20608
the distal cord	20608
bettaIII neuron-specific tubulin -LRB- bIIIT -RRB- , and -LRB- d , e -RRB- neurofilament 200 -LRB- NF200 -RRB-	20653
bettaIII neuron-specific tubulin -LRB- bIIIT -RRB- , and -LRB- d , e -RRB- neurofilament 200	20653
bettaIII neuron-specific tubulin -LRB- bIIIT -RRB- ,	20653
bettaIII neuron-specific tubulin	20653
bIIIT	20687
d	20700
e	20702
neurofilament 200	20705
NF200	20724
i : A large proportion of	20734
i	20734
A large proportion of	20737
A large proportion	20737
these	20759
projections from the brainstem expressing serotonin -LRB- 5HT ; f , g -RRB- and tyrosine hydroxylase -LRB- TH ; h , i -RRB-	20770
projections	20770
the brainstem expressing serotonin -LRB- 5HT ; f , g -RRB- and tyrosine hydroxylase -LRB- TH ; h , i -RRB-	20787
the brainstem	20787
serotonin -LRB- 5HT ; f , g -RRB- and tyrosine hydroxylase -LRB- TH ; h , i -RRB-	20812
serotonin -LRB- 5HT ; f , g -RRB-	20812
serotonin	20812
5HT ; f , g	20823
5HT	20823
f , g	20828
f	20828
g	20830
tyrosine hydroxylase -LRB- TH ; h , i -RRB-	20837
tyrosine hydroxylase	20837
TH ; h , i	20859
TH	20859
h , i	20863
h	20863
which	20869
the most robust	20888
response	20914
g , i : In numerous instances , these axons crossed the caudal lesion -- host interface -LRB- arrows -RRB- , sometimes extending several millimeters distally .	20924
g , i	20924
g	20924
i	20926
numerous instances	20932
these axons	20952
the caudal lesion -- host interface -LRB- arrows -RRB-	20972
the caudal lesion	20972
host interface -LRB- arrows -RRB-	20990
host interface	20990
arrows	21006
several millimeters	21035
j , k : Sensory afferents expressing calcitonin gene-related peptide -LRB- CGRP -RRB- grew into the OEC-treated lesion site but typically failed to enter intact host spinal cord .	21065
j , k	21065
j	21065
k	21067
Sensory afferents expressing calcitonin gene-related peptide -LRB- CGRP -RRB- grew into the OEC-treated lesion site but typically failed to enter intact host spinal cord	21070
Sensory afferents	21070
calcitonin gene-related peptide -LRB- CGRP -RRB-	21099
calcitonin gene-related peptide	21099
CGRP	21132
the OEC-treated lesion site	21148
intact host spinal cord	21206
Scale	21231
= 250 µm in a -LRB- applies to a , b , d , f , h , j -RRB- ; boxes = 350 µ wide areas of e -- k. Fig. 5	21241
= 250 µm	21241
250	21243
a -LRB- applies to a , b , d , f , h , j -RRB- ; boxes = 350 µ wide areas	21253
a -LRB- applies to a , b , d , f , h , j -RRB-	21253
a	21253
a , b , d , f , h , j	21267
a	21267
b	21269
d	21271
f	21273
h	21275
j	21277
boxes = 350 µ wide areas	21281
boxes	21281
= 350 µ wide areas	21287
Fig. 5	21315
Rubrospinal axons	21323
limited regeneration	21353
rats that received olfactory ensheathing cell -LRB- OEC -RRB- transplants	21377
rats	21377
olfactory ensheathing cell -LRB- OEC -RRB- transplants	21396
OEC	21424
a , b : Seven days after medium injection , rubrospinal axons -LRB- detected by biotinylated dextran amine ; red -RRB- were segregated at the rostral border of the cavitation ; whereas some of these axons assumed a random path characteristic of axonal sprouts , most displayed morphologic characteristics of end-bulbs -LRB- arrows -RRB- .	21442
a , b	21442
a	21442
b	21444
Seven days after medium injection , rubrospinal axons -LRB- detected by biotinylated dextran amine ; red -RRB- were segregated at the rostral border of the cavitation	21447
Seven days	21447
medium injection , rubrospinal axons -LRB- detected by biotinylated dextran amine ; red -RRB-	21464
medium injection	21464
rubrospinal axons	21482
dextran amine ; red	21526
dextran amine	21526
red	21541
the rostral border of the cavitation	21565
the rostral border	21565
the cavitation	21587
whereas some of these axons assumed a random path characteristic of axonal sprouts , most displayed morphologic characteristics of end-bulbs -LRB- arrows -RRB-	21603
whereas some of these axons assumed a random path characteristic of axonal sprouts , most displayed morphologic characteristics of end-bulbs	21603
some of these axons	21611
some	21611
these axons	21619
a random path characteristic of axonal sprouts	21639
a random path characteristic	21639
axonal sprouts	21671
most displayed morphologic characteristics of end-bulbs	21687
most	21687
morphologic characteristics of end-bulbs	21702
morphologic characteristics	21702
end-bulbs	21733
arrows	21744
c : Seven days	21753
c	21753
Seven days	21756
enhanced green fluorescent protein-positive OEC transplantation	21773
green	21838
fewer rubrospinal axons	21846
the vicinity of the lesion site	21884
the vicinity	21884
the lesion site	21900
medium controls	21930
d	21947
28 days after medium injection	21953
28 days	21953
medium injection	21967
rubrospinal axons	21985
close proximity to the rostral edge of the lesion	22017
close proximity	22017
the rostral edge of the lesion	22036
the rostral edge	22036
the lesion	22056
the lesion	22102
e , f : Twenty-eight days after OEC transplantation -LRB- green -RRB- , many axons remained stalled more rostrally than in medium controls ; however , a few axons were detected in the OEC-filled lesion site .	22114
e , f : Twenty-eight days after OEC transplantation -LRB- green -RRB- , many axons remained stalled more rostrally than in medium controls	22114
f : Twenty-eight days after OEC transplantation -LRB- green -RRB- , many axons remained stalled more rostrally than in medium controls	22116
f	22116
Twenty-eight days	22119
OEC transplantation -LRB- green -RRB-	22143
OEC transplantation	22143
many axons	22172
medium controls	22223
a few axons	22249
the OEC-filled lesion site	22278
g	22306
Sixty days	22309
medium injection	22326
rubrospinal axons	22344
the cavitation	22373
autofluorescent macrophages -LRB- yellow ; n = 3 -RRB-	22394
autofluorescent macrophages	22394
yellow ; n = 3	22423
yellow	22423
n = 3	22431
n	22431
3	22435
h , i : Sixty days after OEC-transplantation , rubrospinal sprouts were found in the modified lesion site but were not seen to cross the caudal lesion -- host interface .	22439
h	22439
i	22441
Sixty days after OEC-transplantation	22444
Sixty days	22444
OEC-transplantation	22461
rubrospinal sprouts	22482
the modified lesion site	22516
the caudal lesion -- host interface	22568
the caudal lesion	22568
host interface	22586
Rostral interface between lesion area and unlesioned spinal cord	22602
Rostral interface	22602
lesion area and unlesioned spinal cord	22628
lesion area	22628
unlesioned spinal cord	22644
each image with an arrowhead	22680
each image	22680
an arrowhead	22696
An asterisk	22710
the center of the lesion site in each panel	22728
the center	22728
the lesion site in each panel	22742
the lesion site	22742
each panel	22761
Scale bars	22773
200 µm in a -LRB- applies to a , c -- e , g , h -RRB- ; 50 µm in b ; 100 µm in f , i. Fig. 6	22786
200 µm	22786
a -LRB- applies to a , c -- e , g , h -RRB- ; 50 µm in b ; 100 µm in f , i. Fig.	22796
a -LRB- applies to a , c -- e , g , h -RRB- ; 50 µm in b ; 100 µm in f ,	22796
a	22796
a , c -- e , g , h -RRB- ; 50 µm in b ; 100	22810
a	22810
c -- e , g , h -RRB- ; 50 µm in b ; 100	22812
c	22812
e , g , h -RRB- ; 50 µm in b ; 100	22815
g , h -RRB- ; 50 µm in b ; 100	22817
g , h -RRB-	22817
g	22817
; 50 µm	22821
50	22823
in b ; 100	22829
in	22829
b	22832
100	22835
f	22845
6	22856
Neoangiogenesis	22859
an endothelial scaffold	22883
glial cells and axonal regeneration	22921
glial cells	22921
axonal regeneration	22937
the lesion site	22960
a , b : Twentyeight days after lamina propria olfactory ensheathing cell -LRB- LP-OEC -RRB- transplantation , the lesion site is surrounded by and filled with the profiles of newly formed rat endothelial cell antigen -LRB- RECA-1 -RRB- - positive vasculature -LRB- red ; arrow in b -RRB- coursing from the laminin-rich -LRB- blue ; arrowhead in b -RRB- lesion : spinal cord interface into the lesion center , where they are closely associated with green fluorescent protein -LRB- GFP -RRB- - positive LP-OECs -LRB- green -RRB- .	22977
a , b	22977
a	22977
b	22979
Twentyeight days after lamina propria olfactory ensheathing cell -LRB- LP-OEC -RRB- transplantation , the lesion site is surrounded by and filled with the profiles of newly formed rat endothelial cell antigen -LRB- RECA-1 -RRB- - positive vasculature -LRB- red ; arrow in b -RRB- coursing from the laminin-rich -LRB- blue ; arrowhead in b -RRB- lesion : spinal cord interface into the lesion center , where they are closely associated with green fluorescent protein -LRB- GFP -RRB- - positive LP-OECs -LRB- green -RRB-	22982
Twentyeight days	22982
lamina propria olfactory ensheathing cell -LRB- LP-OEC -RRB- transplantation , the lesion site is surrounded by and filled with the profiles of newly formed rat endothelial cell antigen -LRB- RECA-1 -RRB- - positive vasculature -LRB- red ; arrow in b -RRB- coursing from the laminin-rich -LRB- blue ; arrowhead in b -RRB- lesion : spinal cord interface into the lesion center , where they are closely associated with green fluorescent protein -LRB- GFP -RRB- - positive LP-OECs -LRB- green -RRB-	23005
lamina propria olfactory ensheathing cell -LRB- LP-OEC -RRB- transplantation , the lesion site is surrounded by and filled with the profiles of newly formed rat endothelial cell antigen -LRB- RECA-1 -RRB-	23005
lamina propria olfactory ensheathing cell -LRB- LP-OEC -RRB- transplantation , the lesion site is surrounded by and filled with the profiles of newly formed rat endothelial cell antigen	23005
lamina propria	23005
olfactory ensheathing cell -LRB- LP-OEC -RRB- transplantation , the lesion site	23020
olfactory ensheathing cell -LRB- LP-OEC -RRB- transplantation	23020
olfactory ensheathing cell	23020
LP-OEC	23048
transplantation	23056
the lesion site	23073
the profiles of newly formed rat	23122
the profiles	23122
newly formed rat	23138
endothelial cell antigen	23155
RECA-1	23181
positive vasculature -LRB- red ; arrow in b -RRB- coursing from the laminin-rich -LRB- blue ; arrowhead in b -RRB- lesion	23190
positive vasculature -LRB- red ; arrow in b -RRB-	23190
positive vasculature	23190
red ; arrow in b	23212
red	23212
arrow in b	23217
arrow	23217
b	23226
the laminin-rich -LRB- blue ; arrowhead in b -RRB- lesion	23243
blue ; arrowhead in b	23261
blue	23261
arrowhead in b	23267
arrowhead	23267
b	23280
spinal cord interface into the lesion center , where they are closely associated with green fluorescent protein -LRB- GFP -RRB- - positive LP-OECs -LRB- green -RRB-	23290
spinal cord interface into the lesion center , where they are closely associated with green fluorescent protein -LRB- GFP -RRB-	23290
spinal cord interface	23290
the lesion center , where they are closely associated with green fluorescent protein -LRB- GFP -RRB-	23317
the lesion center	23317
they	23342
green fluorescent protein -LRB- GFP -RRB-	23375
green fluorescent protein	23375
GFP	23402
positive LP-OECs -LRB- green -RRB-	23408
positive LP-OECs	23408
c	23434
a region of the section where GFP-positive cells are no longer found -LRB- region marked by double asterisks on a -RRB-	23440
a region	23440
the section where GFP-positive cells are no longer found -LRB- region marked by double asterisks on a -RRB-	23452
the section where GFP-positive cells are no longer found	23452
the section	23452
GFP-positive cells	23470
region marked by double asterisks on a	23510
region	23510
double asterisks	23527
rat p75-positive -LRB- green -RRB- Schwann cells	23551
the rich laminin -LRB- red -RRB- boundary	23623
red	23641
developing endothelia -LRB- cores of blood vessels are marked with asterisks -RRB-	23667
developing endothelia	23667
cores of blood vessels	23690
cores	23690
blood vessels	23699
asterisks	23729
d : Some rat p75-positive Schwann cells also immunopositive for the type V collagen isoform p200 , which is up-regulated in Schwann cells stimulating regeneration -LRB- yellow on overlap ; arrow -RRB- .	23741
d	23741
Some rat p75-positive Schwann cells also immunopositive for the type V collagen isoform p200 , which is up-regulated in Schwann cells stimulating regeneration -LRB- yellow on overlap ; arrow -RRB-	23744
Some rat	23744
p75-positive Schwann cells also	23753
p75-positive Schwann cells	23753
the type V collagen isoform p200 , which is up-regulated in Schwann cells stimulating regeneration -LRB- yellow on overlap ; arrow -RRB-	23804
the type V collagen isoform p200	23804
Schwann cells stimulating regeneration -LRB- yellow on overlap ; arrow -RRB-	23863
Schwann cells	23863
regeneration	23889
arrow	23922
DAPI , 4 ,6 - diamidine-2-phenylidole-dihydrochloride -RRB- .	23930
DAPI , 4 ,6	23930
diamidine-2-phenylidole-dihydrochloride	23942
Neurofilament 200 -LRB- NF200 -RRB- - positive axons -LRB- blue ; arrowheads -RRB- fasciculate and extend along the RECA-1 -- positive -LRB- red -RRB- vasculature toward the GFP-positive LP-OECs -LRB- green -RRB-	23987
Neurofilament	23987
200 -LRB- NF200 -RRB- - positive axons -LRB- blue ; arrowheads -RRB-	24001
200 -LRB- NF200 -RRB-	24001
positive axons	24014
blue ; arrowheads	24030
blue	24030
arrowheads	24036
fasciculate and extend along the RECA-1 -- positive -LRB- red -RRB- vasculature toward the GFP-positive LP-OECs -LRB- green -RRB-	24048
fasciculate	24048
extend along the RECA-1 -- positive -LRB- red -RRB- vasculature toward the GFP-positive LP-OECs -LRB- green -RRB-	24064
the RECA-1	24077
positive -LRB- red -RRB- vasculature toward the GFP-positive LP-OECs -LRB- green -RRB-	24088
positive -LRB- red -RRB- vasculature	24088
the GFP-positive LP-OECs -LRB- green -RRB-	24122
the GFP-positive LP-OECs	24122
higher magnification -LRB- from boxed area in e -RRB- , NF200-positive axons -LRB- blue ; arrowhead -RRB- at the caudal boundary of the lesion directionally follow along both RECA-1 -- positive blood vessels -LRB- red ; arrow -RRB- and their associated GFP-positive LP-OECs -LRB- asterisk -RRB-	24162
higher magnification	24162
boxed area in e -RRB- , NF200-positive axons -LRB- blue ; arrowhead -RRB- at the caudal boundary of the lesion directionally follow along both RECA-1 -- positive blood vessels -LRB- red ; arrow	24189
boxed area	24189
e -RRB- , NF200-positive axons -LRB- blue ; arrowhead -RRB- at the caudal boundary of the lesion directionally follow along both RECA-1 -- positive blood vessels -LRB- red ; arrow	24203
e -RRB- , NF200-positive axons -LRB- blue ; arrowhead -RRB- at the caudal boundary of the lesion directionally follow along both RECA-1	24203
NF200-positive axons -LRB- blue ; arrowhead -RRB- at the caudal boundary of the lesion directionally follow along both RECA-1	24207
NF200-positive axons -LRB- blue ; arrowhead -RRB-	24207
NF200-positive axons	24207
blue ; arrowhead	24229
blue	24229
arrowhead	24235
the caudal boundary of the lesion directionally follow along both RECA-1	24249
the caudal boundary	24249
the lesion directionally follow along both RECA-1	24272
both RECA-1	24310
positive blood vessels -LRB- red ; arrow	24322
positive blood vessels	24322
red ; arrow	24346
red	24346
arrow	24351
their associated GFP-positive LP-OECs -LRB- asterisk -RRB-	24362
their associated GFP-positive LP-OECs	24362
asterisk	24401
Scale bars = 200 µm in a , e ; 100 µm in b -- d , f. Fig. 7 .	24412
Scale bars	24412
= 200 µm in a , e ; 100 µm in b -- d , f. Fig. 7 .	24423
= 200 µm	24423
200	24425
a , e ; 100 µm in b -- d , f. Fig. 7 .	24435
100 µm	24440
b -- d , f. Fig. 7	24450
b	24450
d , f. Fig. 7	24452
d	24452
f. Fig. 7	24454
f. Fig.	24454
7	24463
Allotransplantation of lamina propria olfactory ensheathing cells -LRB- LP-OECs -RRB-	24466
Allotransplantation of lamina propria olfactory ensheathing cells	24466
Allotransplantation	24466
lamina propria olfactory ensheathing cells	24489
LP-OECs	24533
glial scar formation	24551
a , b : At 28 days after lesion , control mice that received medium alone show only a few p75-positive cells -LRB- red -RRB- near the lesion site -LRB- a -RRB- , whereas mice that received green fluorescent protein -LRB- GFP -RRB- - positive OECs -LRB- not visible on this section -RRB- have numerous p75 - positive presumptive Schwann cells -LRB- red -RRB- that infiltrate and migrate -LRB- arrow in b -RRB- out into surrounding spinal cord -LRB- b -RRB- .	24603
a , b	24603
a	24603
b	24605
At 28 days after lesion , control mice that received medium alone show only a few p75-positive cells -LRB- red -RRB- near the lesion site -LRB- a -RRB- , whereas mice that received green fluorescent protein -LRB- GFP -RRB- - positive OECs -LRB- not visible on this section -RRB- have numerous p75 - positive presumptive Schwann cells -LRB- red -RRB- that infiltrate and migrate -LRB- arrow in b -RRB- out into surrounding spinal cord -LRB- b -RRB-	24608
At 28 days	24608
lesion	24625
control mice that received medium alone show only a few p75-positive cells -LRB- red -RRB- near the lesion site -LRB- a -RRB- , whereas mice that received green fluorescent protein -LRB- GFP -RRB- - positive OECs -LRB- not visible on this section -RRB- have numerous p75 - positive presumptive Schwann cells -LRB- red -RRB- that infiltrate and migrate -LRB- arrow in b -RRB- out into surrounding spinal cord -LRB- b -RRB-	24633
control mice	24633
medium	24660
only a few p75-positive cells -LRB- red -RRB-	24678
only a few p75-positive cells	24678
red	24709
the lesion site	24719
-LRB- a -RRB- , whereas mice that received green fluorescent protein -LRB- GFP -RRB- - positive OECs -LRB- not visible on this section -RRB- have numerous p75 - positive presumptive Schwann cells -LRB- red -RRB- that infiltrate	24735
-LRB- a -RRB- , whereas mice that received green fluorescent protein -LRB- GFP -RRB- - positive OECs -LRB- not visible on this section -RRB- have numerous p75	24735
mice that received green fluorescent protein -LRB- GFP -RRB- - positive OECs -LRB- not visible on this section -RRB-	24748
mice that received green fluorescent protein -LRB- GFP -RRB- - positive OECs	24748
mice	24748
green fluorescent protein -LRB- GFP -RRB- - positive OECs	24767
green fluorescent protein	24767
GFP	24794
positive OECs	24800
this section	24830
numerous p75	24849
positive presumptive Schwann cells -LRB- red -RRB- that infiltrate	24863
positive presumptive Schwann cells -LRB- red -RRB-	24863
positive presumptive Schwann cells	24863
red	24899
arrow in b	24933
arrow	24933
b	24942
spinal cord	24966
b	24979
c , d : Astrocytes -LRB- glial fibrillary acidic protein -LSB- GFAP -RSB- , red -RRB- cluster in a scar formation close to the center of the lesion -LRB- c -RRB- , whereas hypertrophic astrocytes -LRB- GFAP , red -RRB- radiate in a broad zone surrounding the lesion -LRB- arrow in d -RRB- , without aligning into a horizontal scar in mice that received transplanted eGFP-positive OECs -LRB- d ; green -RRB- .	24983
c , d	24983
c	24983
d	24985
Astrocytes -LRB- glial fibrillary acidic protein -LSB- GFAP -RSB- , red -RRB- cluster in a scar formation close to the center of the lesion -LRB- c -RRB- , whereas hypertrophic astrocytes -LRB- GFAP , red -RRB- radiate in a broad zone surrounding the lesion -LRB- arrow in d -RRB- , without aligning into a horizontal scar in mice that received transplanted eGFP-positive OECs -LRB- d ; green -RRB-	24988
Astrocytes -LRB- glial fibrillary acidic protein -LSB- GFAP -RSB- , red -RRB- cluster	24988
Astrocytes -LRB- glial fibrillary acidic protein -LSB- GFAP -RSB- , red -RRB-	24988
Astrocytes	24988
glial fibrillary acidic protein -LSB- GFAP -RSB- , red	25000
glial fibrillary acidic protein -LSB- GFAP -RSB-	25000
red	25040
a scar formation close to the center of the lesion -LRB- c -RRB- , whereas hypertrophic astrocytes -LRB- GFAP , red -RRB- radiate in a broad zone surrounding the lesion -LRB- arrow in d -RRB- , without aligning into a horizontal scar in mice that received transplanted eGFP-positive OECs -LRB- d ; green -RRB-	25056
a scar formation close	25056
the center of the lesion -LRB- c -RRB- , whereas hypertrophic astrocytes -LRB- GFAP , red -RRB- radiate in a broad zone surrounding the lesion -LRB- arrow in d -RRB- , without aligning into a horizontal scar in mice that received transplanted eGFP-positive OECs -LRB- d ; green -RRB-	25082
the center	25082
the lesion -LRB- c -RRB- , whereas hypertrophic astrocytes -LRB- GFAP , red -RRB- radiate in a broad zone surrounding the lesion -LRB- arrow in d -RRB- , without aligning into a horizontal scar in mice that received transplanted eGFP-positive OECs -LRB- d ; green -RRB-	25096
the lesion	25096
-LRB- c -RRB- , whereas hypertrophic astrocytes -LRB- GFAP , red -RRB- radiate in a broad zone surrounding the lesion -LRB- arrow in d -RRB-	25107
hypertrophic astrocytes -LRB- GFAP , red -RRB-	25120
hypertrophic astrocytes	25120
GFAP , red	25145
GFAP	25145
red	25151
a broad zone surrounding the lesion -LRB- arrow in d -RRB-	25167
a broad zone	25167
the lesion -LRB- arrow in d -RRB-	25192
the lesion	25192
arrow in d	25204
arrow	25204
d	25213
a horizontal scar in mice that received transplanted eGFP-positive OECs -LRB- d ; green -RRB-	25239
a horizontal scar	25239
mice that received transplanted eGFP-positive OECs -LRB- d ; green -RRB-	25260
mice	25260
transplanted eGFP-positive OECs	25279
d ; green	25312
d	25312
green	25315
e , f : In control mice -LRB- e -RRB- , sparse neurofilament 200 -LRB- NF200 -RRB- - positive axons are seen near the lesion center , whereas in OEC-transplanted mice 28 days after lesion -LRB- f -RRB- , a significant population of neurofilament-positive axons -LRB- red -RRB- grow into the center of the lesion site from all directions -LRB- arrowhead in f -RRB- .	25323
e , f : In control mice -LRB- e -RRB- , sparse neurofilament 200 -LRB- NF200 -RRB- - positive axons are seen near the lesion center , whereas in OEC-transplanted mice 28 days after lesion	25323
f : In control mice -LRB- e -RRB- , sparse neurofilament 200 -LRB- NF200 -RRB- - positive axons are seen near the lesion center , whereas in OEC-transplanted mice 28 days after lesion	25325
f	25325
control mice -LRB- e -RRB- , sparse neurofilament 200 -LRB- NF200 -RRB- - positive axons are seen near the lesion center , whereas in OEC-transplanted mice 28 days after lesion	25331
control mice	25331
-LRB- e -RRB- , sparse neurofilament 200 -LRB- NF200 -RRB- - positive axons are seen near the lesion center , whereas in OEC-transplanted mice 28 days after lesion	25344
sparse neurofilament 200 -LRB- NF200 -RRB- - positive axons are seen near the lesion center , whereas in OEC-transplanted mice 28 days after lesion	25349
sparse neurofilament 200 -LRB- NF200 -RRB-	25349
sparse neurofilament	25349
200 -LRB- NF200 -RRB-	25370
positive axons	25383
the lesion center , whereas in OEC-transplanted mice	25412
the lesion center	25412
OEC-transplanted mice	25442
28 days	25464
lesion	25478
-LRB- f -RRB- , a significant population of neurofilament-positive axons -LRB- red -RRB- grow into the center of the lesion site from all directions -LRB- arrowhead in f -RRB-	25485
a significant population of neurofilament-positive axons -LRB- red -RRB- grow into the center of the lesion site from all directions -LRB- arrowhead in f -RRB-	25490
a significant population	25490
neurofilament-positive axons -LRB- red -RRB- grow into the center of the lesion site from all directions -LRB- arrowhead in f -RRB-	25518
neurofilament-positive axons -LRB- red -RRB-	25518
neurofilament-positive axons	25518
red	25548
the center of the lesion site	25563
the center	25563
the lesion site	25577
all directions -LRB- arrowhead in f -RRB-	25598
all directions	25598
arrowhead in f	25614
arrowhead	25614
f	25627
g , h : Although serotonin -LRB- 5HT -RRB- - positive axons are seen at the surface of the spinal cord in controls -LRB- arrowhead in g -RRB- , a more significant population can be found crossing the rostral host -- lesion interface to enter the core of the lesion site in mice that received GFP-OEC -LRB- green -RRB- transplants -LRB- arrows in h -RRB- .	25631
g , h	25631
g	25631
h	25633
serotonin -LRB- 5HT -RRB-	25645
serotonin	25645
5HT	25656
positive axons	25662
the surface of the spinal cord in controls -LRB- arrowhead in g -RRB-	25689
the surface	25689
the spinal cord in controls -LRB- arrowhead in g -RRB-	25704
the spinal cord	25704
controls -LRB- arrowhead in g -RRB-	25723
controls	25723
arrowhead in g	25733
arrowhead	25733
g	25746
a more significant population	25750
the rostral host	25802
lesion interface	25819
the core of the lesion site	25845
the core	25845
the lesion site	25857
mice that received GFP-OEC -LRB- green -RRB- transplants -LRB- arrows in h -RRB-	25876
mice	25876
GFP-OEC	25895
-LRB- green -RRB- transplants -LRB- arrows in h -RRB-	25903
-LRB- green -RRB- transplants	25903
arrows in h	25924
arrows	25924
h	25934
Scale	25938
= 200 µm in a -LRB- applies to a -- h -RRB-	25948
= 200 µm	25948
200	25950
a	25960
a -- h	25974
h	25976
well-characterized , trackable OECs that could be used for a series of cross-comparative transplantation studies	25991
well-characterized , trackable OECs	25991
a series of cross-comparative transplantation studies	26049
a series	26049
cross-comparative transplantation studies	26061
we	26104
a novel approach	26123
LP-OECs -LRB- Au and Roskams , 2003 -RRB- , which we further applied to homozygous mice expressing eGFP driven by a CMV : betta-actin promoter	26162
LP-OECs -LRB- Au and Roskams , 2003 -RRB-	26162
LP-OECs	26162
Au and Roskams	26171
2003	26187
we	26200
homozygous mice	26222
eGFP driven by a CMV : betta-actin promoter	26249
eGFP	26249
a CMV	26264
betta-actin promoter	26270
We	26292
their retention of maximal eGFP expression in conjunction	26310
their retention	26310
maximal eGFP expression in conjunction	26329
maximal eGFP expression	26329
conjunction	26356
changes in antigenic and morphologic phenotype	26383
changes	26383
antigenic and morphologic phenotype	26394
successive passages -LRB- Okabe et al. , 1997 -RRB-	26438
successive passages	26438
Okabe	26459
et al. , 1997	26465
et al.	26465
1997	26473
All LP-OECs subsequently used in transplantation	26480
All LP-OECs	26480
transplantation	26513
24 hours	26541
transplantation	26557
98 -- 100 % pure OECs by both antigenic and morphologic analysis	26603
98	26603
100 % pure OECs by both antigenic and morphologic analysis	26606
100 % pure OECs	26606
both antigenic and morphologic analysis	26624
immunocytochemical analysis	26668
virtually all OECs	26697
readily detectable levels of p75 -LRB- 97.9 ± 2.2 % -RRB- the cytoskeletal marker , S100betta -LRB- 99.5 ± 1.6 % -RRB- and diffuse , lower expression of glial fibrillary acidic protein -LRB- GFAP -RRB-	26726
readily detectable levels	26726
p75 -LRB- 97.9 ± 2.2 % -RRB- the cytoskeletal marker , S100betta -LRB- 99.5 ± 1.6 % -RRB- and diffuse , lower expression of glial fibrillary acidic protein -LRB- GFAP -RRB-	26755
p75 -LRB- 97.9 ± 2.2 % -RRB- the cytoskeletal marker	26755
p75 -LRB- 97.9 ± 2.2 % -RRB-	26755
p75	26755
97.9 ± 2.2 %	26760
97.9	26760
2.2 %	26767
the cytoskeletal marker	26773
S100betta -LRB- 99.5 ± 1.6 % -RRB- and diffuse	26798
S100betta -LRB- 99.5 ± 1.6 % -RRB-	26798
S100betta	26798
99.5 ± 1.6 %	26809
99.5	26809
1.6 %	26816
diffuse	26826
lower expression of glial fibrillary acidic protein -LRB- GFAP -RRB-	26835
lower expression	26835
glial fibrillary acidic protein -LRB- GFAP -RRB-	26855
glial fibrillary acidic protein	26855
GFAP	26888
addition	26897
significant eGFP fluorescence	26909
No significant differences in morphology or antigenicity	26940
No significant differences	26940
morphology or antigenicity	26970
LP-OECs cultured fresh	27019
LP-OECs	27019
three times -LRB- i.e. , at 4 DIV , 8 DIV , and 12 DIV -RRB- , compared with those frozen after 9 DIV and passaged four times -LRB- data not shown ; Au and Roskams , 2003 -RRB-	27055
three times -LRB- i.e. , at 4 DIV , 8 DIV , and 12 DIV -RRB-	27055
i.e. , at 4 DIV , 8 DIV , and 12 DIV	27068
i.e.	27068
4 DIV , 8 DIV	27077
4 DIV	27077
8 DIV	27084
12 DIV	27095
those frozen after 9 DIV and passaged four times -LRB- data not shown ; Au and Roskams , 2003 -RRB-	27118
those	27118
9 DIV	27137
four times -LRB- data not shown ; Au and Roskams , 2003 -RRB-	27156
four	27156
times -LRB- data not shown ; Au and Roskams , 2003 -RRB-	27161
times	27161
data not shown ; Au and Roskams , 2003	27168
data not shown	27168
data	27168
Au and Roskams , 2003	27184
Au and Roskams	27184
2003	27200
LP-OECs	27207
cavity formation	27236
limited migration and survival	27269
the spinal cord All initial transplantation experiments of mouse LPOECs were performed in a rat lesion because the rat post-lesion spinal cord pathology reflects the most common features of spinal cord pathology reported in human SCI	27303
the spinal cord	27303
All initial transplantation experiments of mouse LPOECs	27319
All initial transplantation experiments	27319
mouse LPOECs	27362
a rat lesion	27393
the rat post-lesion spinal cord pathology	27414
the rat	27414
post-lesion spinal cord pathology	27422
the most common features of spinal cord pathology reported in human SCI	27465
the most common features	27465
spinal cord pathology reported in human SCI	27493
spinal cord pathology	27493
human SCI	27527
addition	27541
testing LP-OEC efficacy in the rat	27551
testing LP-OEC efficacy	27551
the rat	27578
us	27594
this repair strategy	27617
others being tested within our laboratories	27643
others	27643
our laboratories	27670
all of the other laboratories transplanting OB-OECs into rat SCI	27696
all	27696
the other laboratories transplanting OB-OECs into rat SCI	27703
the other laboratories	27703
OB-OECs	27740
rat SCI	27753
This strategy	27762
us	27792
cross-species transplantation of LP-OECs into a CNS environment	27806
cross-species transplantation	27806
LP-OECs into a CNS environment	27839
LP-OECs	27839
a CNS environment	27852
a feasible clinical approach in the context of an appropriate immunosuppression paradigm	27879
a feasible clinical approach	27879
the context of an appropriate immunosuppression paradigm	27911
the context	27911
an appropriate immunosuppression paradigm	27926
A total of 75,000 -- 150,000 LP-OECs from passages 3 -- 5	27969
A total of 75,000 -- 150,000 LP-OECs from passages	27969
A total of 75,000	27969
A total	27969
75,000	27980
150,000 LP-OECs from passages	27987
150,000 LP-OECs	27987
passages	28008
3 -- 5	28017
the site of an acute lesion of the dorsolateral funiculus in immune-suppressed adult male Sprague-Dawley rats	28053
the site	28053
an acute lesion of the dorsolateral funiculus in immune-suppressed adult male Sprague-Dawley rats	28065
an acute lesion	28065
the dorsolateral funiculus in immune-suppressed adult male Sprague-Dawley rats	28084
the dorsolateral funiculus	28084
immune-suppressed adult male Sprague-Dawley rats	28114
Horizontal sections through the lesion site	28164
Horizontal sections	28164
the lesion site	28192
lesion volume , cavity formation , and migration of transplanted cells -LRB- Fig. 1 -RRB-	28233
lesion volume	28233
cavity formation	28248
migration of transplanted cells -LRB- Fig. 1 -RRB-	28270
migration	28270
transplanted cells -LRB- Fig. 1 -RRB-	28283
transplanted cells	28283
Fig. 1	28303
control rats -LRB- DMEM/F12 alone -RRB-	28315
control rats	28315
DMEM/F12	28329
a cavity	28346
the site of injury	28365
the site	28365
injury	28377
the first week -LRB- Fig. 1a , c -RRB- , which resembled that seen in rats with lesion but no medium -LRB- W. Tetzlaff , unpublished observation -RRB-	28391
the first week -LRB- Fig. 1a , c -RRB-	28391
the first week	28391
Fig. 1a , c	28407
Fig. 1a	28407
c	28415
that seen in rats with lesion but no medium -LRB- W. Tetzlaff , unpublished observation -RRB-	28435
that	28435
rats with lesion but no medium -LRB- W. Tetzlaff , unpublished observation -RRB-	28448
rats	28448
lesion but no medium -LRB- W. Tetzlaff , unpublished observation -RRB-	28458
lesion	28458
no medium -LRB- W. Tetzlaff , unpublished observation -RRB-	28469
no medium	28469
W. Tetzlaff	28480
unpublished observation	28493
The size of the cavity	28519
The size	28519
the cavity	28531
28 days	28557
maximal diameters of 0.5 to 1 mm -LRB- Fig. 1e , g -RRB-	28575
maximal diameters	28575
0.5 to 1 mm -LRB- Fig. 1e , g -RRB-	28596
0.5 to 1 mm	28596
Fig. 1e , g	28609
Fig. 1e	28609
g	28617
contrast	28624
cavity formation	28634
reduced -LRB- and usually absent -RRB- in animals that received OEC injections -LRB- Fig. 1b , d , f , h -RRB-	28669
reduced -LRB- and usually absent -RRB-	28669
reduced	28669
animals that received OEC injections -LRB- Fig. 1b , d , f , h -RRB-	28701
animals	28701
OEC injections	28723
Fig. 1b , d , f , h	28739
Fig. 1b	28739
d	28747
f	28749
h	28751
Measurement of cavity area in horizontal sections of the spinal cord	28755
Measurement	28755
cavity area in horizontal sections of the spinal cord	28770
cavity area	28770
horizontal sections of the spinal cord	28785
horizontal sections	28785
the spinal cord	28808
a more than 99 % reduction -LRB- P < 0.001 -RRB-	28833
a more than 99 % reduction	28833
P < 0.001	28860
P	28860
< 0.001	28862
<	28862
0.001	28864
day 28 after lesion in rats that had received LP-OEC transplants , where the average cavity area in control rats was 0.735 ± 0.293 mm2 and , in animals that received OECs , 0.01 ± 0.004 mm2	28874
day 28	28874
lesion in rats that had received LP-OEC transplants , where the average cavity area in control rats was 0.735	28887
lesion	28887
rats that had received LP-OEC transplants , where the average cavity area in control rats was 0.735	28897
rats	28897
LP-OEC transplants , where the average cavity area in control rats was 0.735	28920
LP-OEC transplants	28920
the average cavity area in control rats	28946
the average cavity area	28946
control rats	28973
0.735	28990
0.293 mm2	28998
animals that received OECs , 0.01	29016
animals	29016
OECs , 0.01	29038
OECs	29038
0.01	29044
0.004 mm2	29051
minimal cavity formation by 28 days after OEC transplantation	29070
minimal cavity formation	29070
28 days after OEC transplantation	29098
28 days	29098
OEC transplantation	29112
the survival and migration of OECs in the spinal cord	29133
the survival and migration	29133
OECs in the spinal cord	29163
OECs	29163
the spinal cord	29171
2 to 28 days	29201
GFP	29224
a stable genetic marker	29231
survival and migration of the injected OECs	29265
survival and migration	29265
the injected OECs	29291
GFP-positive OECs	29310
the center of the lesion site 2 days	29357
the center	29357
the lesion site	29371
2 days	29387
transplantation	29400
migratory streams of OECs	29421
migratory streams	29421
OECs	29442
the host tissue	29471
700 m	29493
the lesion epicenter -LRB- Fig. 1b -RRB-	29505
the lesion epicenter	29505
Fig. 1b	29527
7 days	29540
these migratory OEC channels	29548
the lesion center into the host tissue -LRB- Fig. 1d -RRB-	29613
the lesion center	29613
the host tissue -LRB- Fig. 1d -RRB-	29636
the host tissue	29636
Fig. 1d	29653
28 days	29670
GFP-positive OECs	29679
more than 400 microns	29719
lesion epicenter -LRB- Fig 1f , i -RRB-	29751
lesion epicenter	29751
Fig 1f	29769
i	29776
GFPpositive OECs	29780
five	29811
nine of the injected rats surviving 28 days	29819
nine	29819
the injected rats surviving 28 days	29827
the injected rats	29827
28 days	29855
none -LRB- 0 of 3 -RRB- of the rats surviving 60 days	29870
none -LRB- 0 of 3 -RRB-	29870
none	29870
0 of 3	29876
0	29876
3	29881
the rats surviving 60 days	29887
the rats	29887
60 days	29906
We	29915
an anti-GFP antibody amplification detection approach	29928
potential down-regulation of GFP	29997
potential down-regulation	29997
GFP	30026
these results	30035
those for endogenous GFP fluorescence , -LRB- data not shown -RRB-	30059
those	30059
endogenous GFP fluorescence	30069
data not shown	30099
data	30099
7 to 60 days after lesion	30121
7 to 60 days	30121
lesion	30140
strongly autofluorescent -LRB- GFPnegative -RRB- cells characteristic of macrophages	30148
strongly autofluorescent -LRB- GFPnegative -RRB- cells	30148
macrophages	30211
the lesion site	30240
the degenerating dorsolateral funiculus	30280
several millimeters from the lesion center both in medium - and cell-injected animals -LRB- Fig. 1g , h -RRB-	30320
several millimeters	30320
the lesion center	30345
medium - and cell-injected animals -LRB- Fig. 1g , h -RRB-	30371
medium - and cell-injected animals	30371
Fig. 1g , h	30406
Fig. 1g	30406
h	30414
the surprising loss of eGFPexpressing OECs compared with the persistence of p75 - positive or dye-labeled OECs reported by others	30424
the surprising loss of eGFPexpressing OECs compared with the persistence of p75	30424
the surprising loss	30424
OECs	30462
the persistence of p75	30481
the persistence	30481
p75	30500
positive or dye-labeled OECs reported by others	30505
positive or dye-labeled OECs	30505
others	30546
we	30554
the possibility that our transplanted OECs	30564
the possibility	30564
our transplanted OECs	30585
eGFP	30621
immunohistochemistry for the common OEC marker , the low affinity nerve growth factor , p75 -LRB- using a polyclonal antibody recognizing both rat and mouse p75 -RRB- , and amplification immunohistochemistry of eGFP	30630
immunohistochemistry for the common OEC marker	30630
immunohistochemistry	30630
the common OEC marker	30655
the low affinity nerve growth factor , p75 -LRB- using a polyclonal antibody recognizing both rat and mouse p75 -RRB-	30678
the low affinity nerve growth factor	30678
p75	30716
a polyclonal antibody recognizing both rat and mouse p75	30727
a polyclonal antibody	30727
rat and mouse p75	30766
amplification immunohistochemistry of eGFP	30790
amplification immunohistochemistry	30790
eGFP	30828
28 days after lesion	30837
28 days	30837
lesion	30851
a dense network of p75-expressing cells -LRB- similar to that reported by others -RRB- , accompanied by NF200-positive axons ,	30859
a dense network	30859
p75-expressing cells -LRB- similar to that reported by others -RRB-	30878
p75-expressing cells	30878
similar to that reported by others	30900
similar	30900
that	30911
others	30928
NF200-positive axons	30952
the center of the lesion site	30991
the center	30991
the lesion site	31005
a pattern that did not correlate with the distribution of eGFP-positive cells -LRB- data not shown -RRB-	31024
a pattern	31024
the distribution of eGFP-positive cells -LRB- data not shown -RRB-	31062
the distribution	31062
eGFP-positive cells	31082
data not shown	31103
data	31103
OEC transplantation	31120
Schwann cell invasion of the lesion site Faced with the conundrum of a significant population of p75-positive/eGFP-negative cells persisting at the lesion site at 28 days after lesion	31149
Schwann cell invasion	31149
the lesion site Faced with the conundrum of a significant population of p75-positive/eGFP-negative cells persisting at the lesion site at 28 days after lesion	31174
the lesion site	31174
the conundrum of a significant population of p75-positive/eGFP-negative cells	31201
the conundrum	31201
a significant population of p75-positive/eGFP-negative cells	31218
a significant population	31218
p75-positive/eGFP-negative cells	31246
the lesion site at 28 days	31293
the lesion site	31293
28 days	31312
lesion	31326
we	31334
the presence of transplanted OECs	31352
the presence	31352
transplanted OECs	31368
other p75 - expressing cells -- such as peripheral host Schwann cells -- to infiltrate into the CNS to participate in the formation of a new transitional zone -LRB- reviewed in Fraher , 1999 -RRB-	31405
cells -- such as peripheral host Schwann cells --	31427
cells	31427
peripheral host Schwann cells	31441
the CNS to participate in the formation of a new transitional zone -LRB- reviewed in Fraher , 1999 -RRB-	31490
the formation of a new transitional zone -LRB- reviewed in Fraher , 1999 -RRB-	31516
the formation	31516
a new transitional zone -LRB- reviewed in Fraher , 1999 -RRB-	31533
a new transitional zone	31533
Fraher , 1999	31570
Fraher	31570
1999	31578
Horizontal tissue sections through the lesion site	31585
Horizontal tissue sections	31585
the lesion site	31620
endogenous -LRB- GFAP , blue ; p75 , red -RRB- and transplanted -LRB- eGFP , green -RRB-	31659
endogenous -LRB- GFAP , blue ; p75 , red -RRB-	31659
endogenous	31659
GFAP , blue ; p75 , red	31671
GFAP	31671
blue ; p75	31677
blue	31677
p75	31683
red	31688
transplanted -LRB- eGFP , green -RRB-	31697
transplanted	31697
eGFP , green	31711
eGFP	31711
green	31717
glial proteins -LRB- Fig. 2 -RRB-	31724
glial proteins	31724
Fig. 2	31740
A monoclonal antibody recognizing a rat-specific form of p75	31749
A monoclonal antibody	31749
a rat-specific form of p75	31783
a rat-specific form	31783
p75	31806
us	31818
host p75-expressing cells from the transplanted GFP-positive mouse OECs	31843
host p75-expressing cells	31843
the transplanted GFP-positive mouse OECs	31874
A significant population of host-derived p75-positive cells resembling migrating Schwann cells	31916
A significant population	31916
host-derived p75-positive cells resembling migrating Schwann cells	31944
host-derived p75-positive cells	31944
Schwann cells	31997
the center of the lesion site , as soon as 7 days after lesion	32028
the center of the lesion site	32028
the center	32028
the lesion site	32042
7 days after lesion	32070
7 days	32070
lesion	32083
transplanted GFPpositive OECs -LRB- Fig. 2a -RRB-	32128
transplanted GFPpositive OECs	32128
Fig. 2a	32159
times	32183
lesion	32195
Schwann cells	32216
the lesion center	32256
the demarcation of a perilesion boundary , in close proximity	32292
the demarcation	32292
a perilesion boundary	32311
close proximity	32337
GFAP-expressing astrocytes -LRB- Fig. 2b , d , e -RRB-	32356
GFAP-expressing astrocytes	32356
Fig. 2b	32384
d	32392
e	32394
all time points after 7 days	32401
all time points	32401
7 days	32423
rat p75-positive Schwann cells	32431
the lesion site	32483
the remaining OECs , interdigitating with other glial cells -LRB- Fig. 2b , d , e -RRB-	32510
the remaining OECs	32510
other glial cells -LRB- Fig. 2b , d , e -RRB-	32551
other glial cells	32551
Fig. 2b	32570
d	32578
e	32580
28 days after lesion -LRB- when remaining transplanted OECs were confined to the center of the lesion site -RRB- , infiltrating Schwann cells aligned at the lesion site boundary in a pattern similar to the initial migratory channels	32587
28 days after lesion -LRB- when remaining transplanted OECs were confined to the center of the lesion site -RRB- , infiltrating Schwann cells	32587
28 days after lesion	32587
28 days	32587
lesion	32601
transplanted OECs	32624
the center of the lesion site	32659
the center	32659
the lesion site	32673
Schwann cells	32704
the lesion site boundary in a pattern similar to the initial migratory channels	32729
the lesion site boundary	32729
a pattern similar to the initial migratory channels	32757
a pattern	32757
the initial migratory channels	32778
transplanted LP-OECs -LRB- Fig. 2f , g -RRB-	32822
transplanted LP-OECs	32822
Fig. 2f , g	32844
Fig. 2f	32844
g	32852
This boundary	32856
a laminin-rich substrate	32894
GFAP-positive astrocytes segregated to the spinal cord side of the lesion -LRB- Fig. 2h , i -RRB- and p75-expressing cells within the lesion boundary -LRB- Fig. 2f , g -RRB-	32925
GFAP-positive astrocytes	32925
the spinal cord side of the lesion -LRB- Fig. 2h , i -RRB- and p75-expressing cells within the lesion boundary -LRB- Fig. 2f , g -RRB-	32964
the spinal cord side	32964
the lesion -LRB- Fig. 2h , i -RRB- and p75-expressing cells within the lesion boundary -LRB- Fig. 2f , g -RRB-	32988
the lesion -LRB- Fig. 2h , i -RRB- and p75-expressing cells within the lesion boundary	32988
Fig. 2h	33000
i	33008
the lesion boundary	33043
Fig. 2f , g	33064
Fig. 2f	33064
g	33072
The rat p75	33076
positive cells	33089
Schwann cells in subsequent experiments	33131
Schwann cells	33131
subsequent experiments	33148
the coincident identification of a subpopulation of cells at the lesion core expressing S100 that were additionally eGFP-negative and GFAP-negative -LRB- data not shown -RRB-	33174
the coincident identification	33174
a subpopulation of cells at the lesion core expressing S100 that were additionally eGFP-negative and GFAP-negative -LRB- data not shown -RRB-	33207
a subpopulation	33207
cells at the lesion core expressing S100 that were additionally eGFP-negative and GFAP-negative -LRB- data not shown -RRB-	33226
cells	33226
the lesion core expressing S100 that were additionally eGFP-negative and GFAP-negative -LRB- data not shown -RRB-	33235
the lesion core	33235
S100 that were additionally eGFP-negative and GFAP-negative	33262
S100	33262
data not shown	33323
data	33323
Astrocytic response to lesion	33340
Astrocytic response	33340
lesion	33363
the presence of LP-OECs and Schwann cells	33384
the presence	33384
LP-OECs and Schwann cells	33400
the dramatic reduction	33432
cavity formation at the lesion site	33458
cavity formation	33458
the lesion site	33478
we	33495
OECs	33508
the formation of a gliotic scar	33530
the formation	33530
a gliotic scar	33547
the lesion boundary	33565
the major barrier	33602
axonal regeneration	33623
spinal cord injury -LRB- Fawcett and Asher , 1999 -RRB-	33649
spinal cord injury	33649
Fawcett and Asher	33669
1999	33688
Schwann cells	33702
OECs	33717
the normal adult CNS	33745
astrocytes in the outer nerve fiber layer of the olfactory bulb	33771
astrocytes	33771
the outer nerve fiber layer of the olfactory bulb	33785
the outer nerve fiber layer	33785
the olfactory bulb	33816
the reactive astrocytic response	33857
some of these mechanisms to reduce gliotic scarring in SCI -LRB- Lakatos et al. , 2000 -RRB-	33929
some	33929
these mechanisms	33937
gliotic scarring	33964
SCI -LRB- Lakatos et al. , 2000 -RRB-	33984
SCI	33984
Lakatos	33989
et al. , 2000	33997
et al.	33997
2000	34005
immunohistochemistry for GFAP and chondroitin sulfate proteoglycans	34022
immunohistochemistry	34022
GFAP and chondroitin sulfate proteoglycans	34047
CSPGs	34091
scar formation	34109
the lesion site -LRB- Fig. 3 -RRB-	34127
the lesion site	34127
Fig. 3	34144
all control animals	34153
both cavity and scar formation	34186
cavity	34191
scar formation	34202
that previously reported -LRB- reviewed in Fawcett and Asher , 1999 ; Steward et al. , 1999 -RRB-	34228
that previously reported	34228
that	34228
Fawcett and Asher , 1999 ; Steward et al. , 1999	34266
Fawcett and Asher , 1999 ; Steward et al.	34266
Fawcett and Asher , 1999	34266
Fawcett and Asher	34266
1999	34285
Steward et al.	34291
Steward	34291
et al.	34299
1999	34307
control rats	34317
the cavity wall	34331
multiple layers of tangentially oriented CSPG-rich deposits	34360
multiple layers	34360
tangentially oriented CSPG-rich deposits	34379
a dense zone of GFAP-positive reactive astrocytes -LRB- Fig. 3a , b -RRB-	34425
a dense zone	34425
GFAP-positive reactive astrocytes -LRB- Fig. 3a , b -RRB-	34441
GFAP-positive reactive astrocytes	34441
Fig. 3a , b	34476
Fig. 3a	34476
b	34484
contrast	34491
rats that received OEC transplants	34501
rats	34501
OEC transplants	34520
a broader , diffuse band of GFAP-positive astrocytes	34549
a broader , diffuse band	34549
GFAP-positive astrocytes	34576
the spinal cord surrounding the lesion site , which terminated in irregular finger-like projections , extending toward the lesion center -LRB- Fig. 3c , d -RRB-	34604
the spinal cord	34604
the lesion site , which terminated in irregular finger-like projections , extending toward the lesion center -LRB- Fig. 3c , d -RRB-	34632
the lesion site	34632
irregular finger-like projections	34669
the lesion center -LRB- Fig. 3c , d -RRB-	34721
the lesion center	34721
Fig. 3c , d	34740
Fig. 3c	34740
d	34748
These astrocyte-filled projections	34752
the channels of Schwann cell-rich projections emanating from the lesion center -LRB- seen in Fig. 2 -RRB-	34807
the channels	34807
Schwann cell-rich projections emanating from the lesion center -LRB- seen in Fig. 2 -RRB-	34823
Schwann cell-rich projections	34823
the lesion center	34868
Fig. 2	34895
the GFAP/CSPG-rich dense scar boundary seen in control animals	34920
the GFAP/CSPG-rich dense scar boundary	34920
control animals	34967
Figs. 2 and 3	34992
Figs. 2	34992
3	35004
CSPG expression around the LP-OEC transplanted lesion site was diffuse and oriented longitudinally along the laminin-rich channels , with CSPG-poor regions within the laminin-rich channels .	35008
CSPG expression around the LP-OEC transplanted lesion site was diffuse and oriented	35008
CSPG expression	35008
the LP-OEC transplanted lesion site was diffuse and oriented	35031
the LP-OEC	35031
transplanted lesion site	35042
the laminin-rich channels	35113
CSPG-poor regions	35145
the laminin-rich channels	35170
gliosis and CSPG deposition	35226
the presence of OECs , and later Schwann cells , at the lesion site	35255
the presence	35255
OECs , and later Schwann cells ,	35271
OECs	35271
Schwann cells	35287
the lesion site	35305
astrocyte and CSPG deposition	35333
longitudinal and radial streams extending from the edge of the lesion	35368
longitudinal and radial streams	35368
the edge of the lesion	35415
the edge	35415
the lesion	35427
the formation of a characteristic dense scar barrier	35452
the formation	35452
a characteristic dense scar barrier	35469
fact	35509
an astrocytic barrier	35535
regeneration	35560
the realigned GFAP-positive astrocytes	35574
permissive	35622
axonal growth	35636
NF200-positive axons	35655
the lesion site	35707
the reorganized	35757
GFAP-positive astrocytes -LRB- Fig. 3e , f -RRB-	35782
GFAP-positive astrocytes	35782
Fig. 3e	35808
f	35816
the origin of these axons	35829
the origin	35829
these axons	35843
many	35875
the host / lesion interface -LRB- Fig. 3e -RRB-	35904
the host / lesion interface	35904
the host	35904
lesion interface	35914
Fig. 3e	35932
Multiple central and peripheral axons	35942
regenerate/sprout in response to LP-OEC transplantation To determine whether this presumably more permissive glial environment may have allowed axonal regeneration or sprouting through the lesion site , we tested for the presence of axons expressing a variety of neuronal markers by immunostaining for axonal antigens	35980
regenerate/sprout	35980
response to LP-OEC transplantation	36001
response	36001
LP-OEC transplantation	36013
this presumably more permissive glial environment	36057
axonal regeneration	36124
the lesion site	36165
we	36182
the presence of axons	36196
the presence	36196
axons	36212
a variety of neuronal markers	36229
a variety	36229
neuronal markers	36242
immunostaining for axonal antigens	36262
immunostaining	36262
axonal antigens	36281
Fig. 4	36298
we	36322
expression of III-tubulin -LRB- IIIT ; neuron-specific tubulin -RRB- , NF200 , 5HT , TH , and CGRP	36334
expression	36334
III-tubulin -LRB- IIIT ; neuron-specific tubulin -RRB- , NF200 , 5HT , TH , and CGRP	36349
III-tubulin -LRB- IIIT ; neuron-specific tubulin -RRB-	36349
III-tubulin	36349
IIIT ; neuron-specific tubulin	36363
IIIT	36363
neuron-specific tubulin	36369
NF200 , 5HT , TH , and CGRP	36395
control animals	36424
axons	36441
the wall	36472
the cavity	36484
the lateral aspect of the lesion -LRB- Fig. 4a -RRB-	36528
the lateral aspect	36528
the lesion -LRB- Fig. 4a -RRB-	36550
the lesion	36550
Fig. 4a	36562
GFP-positive OECs	36581
60 days	36630
all rats that had received OEC injections	36639
all rats	36639
OEC injections	36666
robust growth of axons	36688
robust growth	36688
axons	36705
the lesion site -LRB- Fig. 4b -- k -RRB-	36716
the lesion site	36716
Fig. 4b -- k	36733
Fig. 4b	36733
k	36741
Axons occupying the lesion site	36745
Axons	36745
the lesion site	36761
diameter	36806
NF200 and IIIT -LRB- Fig. 4b -- e -RRB-	36831
NF200 and IIIT	36831
Fig. 4b -- e	36848
Fig. 4b	36848
e	36856
Sprouting axons at the lesion center	36860
Sprouting axons	36860
the lesion center	36879
both the CNS and PNS	36913
expression of 5HT , TH , and CGRP -LRB- Fig. 4f -- k -RRB-	36951
expression	36951
5HT , TH , and CGRP -LRB- Fig. 4f -- k -RRB-	36965
5HT , TH , and CGRP	36965
Fig. 4f -- k	36984
Fig. 4f	36984
k	36993
The orientation of axons in the lesion site	36997
The orientation	36997
axons in the lesion site	37016
axons	37016
the lesion site	37025
their site of origin	37063
their site	37063
origin	37077
central axons assuming a bias to an axis perpendicular to the dorsal columns and peripheral axons running laterally across the lesion site	37090
central axons	37090
a bias	37113
an axis perpendicular to the dorsal columns and peripheral axons running laterally across the lesion site	37123
an axis	37123
the dorsal columns and peripheral axons running laterally across the lesion site	37148
the dorsal columns	37148
peripheral axons running laterally across the lesion site	37171
peripheral axons	37171
the lesion site	37213
IIIT-positive axons	37231
the center of the OEC-treated lesion site -LRB- Fig. 4b , c -RRB-	37280
the center	37280
the OEC-treated lesion site -LRB- Fig. 4b , c -RRB-	37294
the OEC-treated lesion site	37294
Fig. 4b , c	37323
Fig. 4b	37323
c	37331
Substantial projections , presumably from the brainstem , expressing 5HT and TH	37335
Substantial projections , presumably from the brainstem ,	37335
Substantial projections	37335
the brainstem	37376
5HT and TH	37402
a typical beaded axonal staining pattern	37423
the glia-rich lesion site	37487
numerous instances	37517
all animals examined	37540
all animals	37540
these axons	37562
the caudal lesion -- host interface -LRB- Fig. 4g , i , arrows -RRB-	37592
the caudal lesion	37592
host interface -LRB- Fig. 4g , i , arrows -RRB-	37610
host interface	37610
Fig. 4g , i , arrows	37626
Fig. 4g	37626
i	37634
arrows	37637
several millimeters	37666
Lateral profiles of sensory afferent axons expressing CGRP	37696
Lateral profiles	37696
sensory afferent axons expressing CGRP	37716
sensory afferent axons	37716
CGRP	37750
the OEC-treated lesion site -LRB- Fig. 4k -RRB-	37784
the OEC-treated lesion site	37784
Fig. 4k	37813
axonal regeneration	37832
the rubrospinal axons	37867
the distal cord At this stage in the analysis , it was clear that transplanted mouse LP-OECs were able to minimize the appar	37913
the distal cord	37913
this stage in the analysis	37932
this stage	37932
the analysis	37946
it	37960
transplanted mouse LP-OECs	37978
the appar	38027
ent hostility of the rat lesion site	38038
ent hostility	38038
the rat lesion site	38055
cavity and scar barrier formation	38089
extensive in-growth of axons of several different phenotypes	38151
extensive in-growth	38151
axons of several different phenotypes	38174
axons	38174
several different phenotypes	38183
the lesion center	38217
Figs. 1 -- 4	38236
Figs. 1	38236
4	38244
the NF200-positive axonal in-growth	38264
regeneration of the axotomized rubrospinal tract in response	38322
regeneration	38322
the axotomized rubrospinal tract in response	38338
the axotomized rubrospinal tract	38338
response	38374
OEC transplantation	38386
we	38407
the tract	38432
BDA in the vicinity of the right red nucleus 1 week	38455
BDA	38455
the vicinity of the right red nucleus 1 week	38462
the vicinity	38462
the right red nucleus	38478
1 week	38500
tracts -LRB- Fig. 5 -RRB-	38544
tracts	38544
Fig. 5	38552
control rats	38564
rubrospinal axons	38578
rostral	38614
the border of the cavity	38625
the border	38625
the cavity	38639
7 days	38650
injury	38663
Fig. 5a	38671
some of these axons	38681
some	38681
these axons	38689
a highly random path characteristic of growing axonal sprouts	38709
a highly random path characteristic	38709
growing axonal sprouts	38748
most axons	38777
morphologic characteristics of end-bulbs -LRB- Fig. 5b -RRB-	38798
morphologic characteristics	38798
end-bulbs -LRB- Fig. 5b -RRB-	38829
end-bulbs	38829
Fig. 5b	38840
rats that received LP-OEC transplants	38853
rats	38853
LP-OEC transplants	38872
fewer axons	38892
the rostral edge of the injury site	38927
the rostral edge	38927
the injury site	38947
none	38968
the OEC transplant	38987
7 days -LRB- Fig. 5c -RRB-	39009
7 days	39009
Fig. 5c	39017
The bulk of the rubrospinal tract	39027
The bulk	39027
the rubrospinal tract	39039
300 m rostral	39067
the lesion center	39085
control animals	39106
short 500 µm rostral	39134
500	39140
the lesion center	39158
OEC transplantation	39181
days 28 and 60	39205
many BDA-filled rubrospinal axons in control animals	39221
many BDA-filled rubrospinal axons	39221
control animals	39258
proximity to the rostral edge of the cavity	39288
proximity	39288
the rostral edge of the cavity	39301
the rostral edge	39301
the cavity	39321
the lesion -LRB- Fig. 5d , g -RRB-	39367
the lesion	39367
Fig. 5d , g	39379
Fig. 5d	39379
g	39387
OEC-treated rats	39394
the majority of the rubrospinal axons	39412
the majority	39412
the rubrospinal axons	39428
several hundred microns proximal to lesion -LRB- e.g. , Fig. 5e -RRB-	39456
several hundred microns	39456
lesion -LRB- e.g. , Fig. 5e -RRB-	39492
lesion	39492
e.g. , Fig. 5e	39500
e.g.	39500
Fig. 5e	39506
28 days after lesion	39519
28 days	39519
lesion	39533
some rubrospinal axons	39541
the center of the lesion occupied by OECs and Schwann cells -LRB- Fig. 5f -RRB-	39580
the center	39580
the lesion occupied by OECs and Schwann cells -LRB- Fig. 5f -RRB-	39594
the lesion	39594
OECs and Schwann cells -LRB- Fig. 5f -RRB-	39617
OECs and Schwann cells	39617
Fig. 5f	39641
Sprouting rubrospinal axons	39651
the center of the lesion at 60 days , -LRB- i.e. , after LP-OECs could no longer be detected ; Fig. 5h , i -RRB-	39702
the center	39702
the lesion at 60 days , -LRB- i.e. , after LP-OECs could no longer be detected ; Fig. 5h , i -RRB-	39716
the lesion	39716
60 days ,	39730
i.e. , after LP-OECs could no longer be detected ; Fig. 5h , i	39740
i.e.	39740
LP-OECs	39752
Fig. 5h	39789
We	39801
rubrospinal axons	39819
the caudal lesion -- host interface at any time ,	39848
the caudal lesion	39848
host interface at any time	39867
host interface	39867
any time	39885
control	39905
OEC-injected animals	39919
STIMULATION OF ANGIOGENESIS BY	39941
STIMULATION	39941
ANGIOGENESIS BY	39956
LP-OECS	39985
A BIOLOGICAL SCAFFOLD TO SUPPORT REGENERATION To test if the `` channels '' formed by migrating glial cells and sprouting axons at the lesion site might represent sites of local angiogenesis	40001
SUPPORT REGENERATION	40026
the `` channels '' formed by migrating glial cells and sprouting axons at the lesion site	40058
the `` channels ''	40058
glial cells	40093
axons	40119
the lesion site	40128
sites of local angiogenesis	40160
sites	40160
local angiogenesis	40169
we	40189
glial and neuronal marker detection	40201
testing	40242
the formation of new vasculature	40254
the formation	40254
new vasculature	40271
an antibody recognizing RECA-1 -LRB- Fig. 6 -RRB-	40292
an antibody	40292
RECA-1 -LRB- Fig. 6 -RRB-	40316
RECA-1	40316
Fig. 6	40324
28 days after LP-OEC transplantation	40336
28 days	40336
LP-OEC transplantation	40350
RECA-1 -- positive blood vessels	40374
RECA-1	40374
positive blood vessels	40382
the lesion site	40416
the laminin-rich spinal cord interface	40452
course	40494
the lesion core where they were in direct contact with both GFP-positive LP-OECs -LRB- Fig. 6a , b -RRB- and were also surrounded by rat p75-positive/p200	40514
the lesion core	40514
they	40536
direct contact with both GFP-positive LP-OECs -LRB- Fig. 6a , b -RRB-	40549
direct contact	40549
GFP-positive LP-OECs	40574
Fig. 6a , b	40596
Fig. 6a	40596
b	40604
rat p75-positive/p200	40635
positive Schwann cells -LRB- Fig. 6c , d -RRB-	40658
positive Schwann cells	40658
Fig. 6c , d	40682
Fig. 6c	40682
d	40690
Axons extending into the lesion center	40694
Axons	40694
the lesion center	40715
stream	40745
RECA-1 -- positive blood vessels	40773
RECA-1	40773
positive blood vessels	40780
direct contacts	40811
transplanted LP-OECs -LRB- Fig. 6e , f -RRB-	40832
transplanted LP-OECs	40832
Fig. 6e	40854
f	40862
Allotransplantation of OECs into lesioned mouse spinal cord Despite the many positive effects stimulated by the cross-species transplantation of mouse LP-OECs into immunosuppressed rat SCI , it could be argued that the limited survival of the LP-OECs and migration patterns reported here that differ significantly from most other reports using vital dye labeling	40866
Allotransplantation	40866
OECs into lesioned mouse spinal cord Despite the many positive effects stimulated by the cross-species transplantation of mouse LP-OECs into immunosuppressed rat SCI , it could be argued that the limited survival of the LP-OECs and migration patterns reported here that differ significantly from most other reports using vital dye labeling	40889
OECs	40889
lesioned mouse spinal cord Despite the many positive effects stimulated by the cross-species transplantation of mouse LP-OECs into immunosuppressed rat SCI , it could be argued that the limited survival of the LP-OECs and migration patterns reported here that differ significantly from most other reports using vital dye labeling	40899
lesioned mouse spinal cord	40899
the many positive effects stimulated by the cross-species transplantation of mouse LP-OECs into immunosuppressed rat SCI	40934
the many positive effects	40934
the cross-species transplantation of mouse LP-OECs	40974
the cross-species transplantation	40974
mouse LP-OECs	41011
immunosuppressed rat SCI	41030
it	41056
the limited survival of the LP-OECs and migration patterns	41080
the limited survival	41080
the LP-OECs and migration patterns	41104
most other reports	41184
vital	41209
labeling	41219
xenotransplantation	41244
The subsequent minimal regeneration of the rubrospinal tract	41265
The subsequent minimal regeneration	41265
the rubrospinal tract	41304
large part	41354
a localized acute immune response in a xenotransplant model	41368
a localized acute immune response	41368
a xenotransplant model	41405
we	41435
identical LP-OECs	41451
those used in rat experiments into a dorsolateral funiculus crush site in nontransgenic C57/Bl6 mice -LRB- the main background strain used to generate the GFP-positive LPOECs -RRB- and treated them with the same immunosuppression paradigm used for the rats -LRB- Fig. 7 -RRB-	41472
those	41472
rat experiments	41486
a dorsolateral funiculus crush site in nontransgenic C57/Bl6 mice -LRB- the main background strain used to generate the GFP-positive LPOECs -RRB-	41507
a dorsolateral funiculus crush site	41507
nontransgenic C57/Bl6 mice	41546
the main background strain used to generate the GFP-positive LPOECs	41574
the main background strain	41574
the GFP-positive LPOECs	41618
them	41655
the same immunosuppression paradigm used for the rats -LRB- Fig. 7 -RRB-	41665
the same immunosuppression paradigm	41665
the rats -LRB- Fig. 7 -RRB-	41710
the rats	41710
Fig. 7	41720
A similar migration to that seen in the rat	41729
A similar migration	41729
that seen in the rat	41752
that	41752
the rat	41765
contrast to the rat transplants	41795
contrast	41795
the rat transplants	41807
GFP-positive LP-OECs	41828
28 days	41871
injection	41885
a spinal cord lesion site in all mice examined -LRB- seven of seven ; Fig. 7b -RRB-	41900
a spinal cord lesion site	41900
all mice examined -LRB- seven of seven ; Fig. 7b -RRB-	41929
all mice	41929
seven of seven ; Fig. 7b	41948
seven	41948
seven ; Fig. 7b	41957
seven	41957
Fig. 7b	41964
the rat	41980
immunosuppression	42006
there	42025
a pronounced infiltration of autofluorescent mononuclear cells	42035
a pronounced infiltration	42035
autofluorescent mononuclear cells	42064
the lesion site -LRB- Fig. 7a , b -RRB-	42103
the lesion site	42103
Fig. 7a , b	42120
Fig. 7a	42120
b	42128
cavitation in this strain of mouse	42140
cavitation	42140
this strain of mouse	42154
this strain	42154
mouse	42169
Steward et al. , 1999	42199
Steward	42199
et al.	42207
1999	42215
the differences in lesion volume	42222
the differences	42222
lesion volume	42241
The zone of GFAP-positive reactive astrocytes surrounding the lesion	42274
The zone	42274
GFAP-positive reactive astrocytes surrounding the lesion	42286
GFAP-positive reactive astrocytes	42286
the lesion	42332
mice that had received GFP-positive LPOEC transplants	42378
mice	42378
GFP-positive LPOEC transplants	42401
the lesion border	42437
no indication of dense scar formation	42465
no indication	42465
dense scar formation	42482
the rat	42510
the infiltration of p75-positive Schwann cells	42519
the infiltration	42519
p75-positive Schwann cells	42539
transplantation of LP-OECs -LRB- Fig. 7c -- f -RRB-	42590
transplantation	42590
LP-OECs -LRB- Fig. 7c -- f -RRB-	42609
LP-OECs	42609
Fig. 7c -- f	42618
Fig. 7c	42618
f	42626
There	42630
a similar significant population of NF200-positive axons entering and crossing the center of the lesion in the treated animals -LRB- Fig. 7f -RRB-	42640
a similar significant population	42640
NF200-positive axons entering and crossing the center of the lesion in the treated animals -LRB- Fig. 7f -RRB-	42676
NF200-positive axons	42676
the center of the lesion in the treated animals -LRB- Fig. 7f -RRB-	42719
the center	42719
the lesion in the treated animals -LRB- Fig. 7f -RRB-	42733
the lesion	42733
the treated animals -LRB- Fig. 7f -RRB-	42747
the treated animals	42747
Fig. 7f	42768
axons	42784
the scar boundary	42802
the lesion center	42845
the control group -LRB- Fig. 7e -RRB- DISCUSSION	42866
Fig. 7e	42885
GFP-expressing	42943
LPOECs transplanted into acute spinal cord injury sites	42959
LPOECs	42959
acute spinal cord injury sites	42984
rats	43018
mice	43027
several novel mechanistic insights as to how OECs create a unique environment to support regeneration	43039
several novel mechanistic insights	43039
OECs	43084
a unique environment to support regeneration	43096
regeneration	43128
These results	43142
LP-OECs	43169
great distances	43200
multiple distinct , novel , and beneficial effects on spinal cord regeneration	43224
multiple distinct , novel , and beneficial effects	43224
spinal cord regeneration	43276
this in a xenotransplantation paradigm	43318
this	43318
a xenotransplantation paradigm	43326
limited migration and short-term survival in host spinal cord after transplantation	43366
limited migration and short-term survival	43366
host spinal cord after transplantation	43411
host spinal cord	43411
transplantation	43434
LP-OECs	43451
cavity formation	43469
glial scar formation	43498
the invasion of host Schwann cells	43532
the invasion	43532
host Schwann cells	43548
a laminin-rich CNS microenvironment that stimulated extensive sprouting and axonal regeneration of multiple motor and sensory axons	43580
a laminin-rich CNS microenvironment that stimulated extensive sprouting	43580
a laminin-rich CNS microenvironment	43580
axonal regeneration of multiple motor and sensory axons	43656
axonal regeneration	43656
multiple motor and sensory axons	43679
multiple motor	43679
sensory axons	43698
Migration patterns of LP-OECs The limited survival and migration of LP-OECs	43713
Migration patterns	43713
LP-OECs The limited survival and migration of LP-OECs	43735
LP-OECs The limited survival	43735
LP-OECs	43735
The limited survival	43743
migration of LP-OECs	43768
migration	43768
LP-OECs	43781
light of previous transplantation studies reporting survival and migration of bulb-derived OECs in host spinal cord for 2 to 8 months -LRB- Li et al. , 1998 ; Ramon - Cueto , 2000 ; Takami et al. , 2002 -RRB-	43812
light	43812
previous transplantation studies reporting survival and migration of bulb-derived OECs in host spinal cord for 2 to 8 months -LRB- Li et al. , 1998 ; Ramon - Cueto , 2000 ; Takami et al. , 2002 -RRB-	43821
previous transplantation studies	43821
survival and migration of bulb-derived OECs	43864
survival and migration	43864
bulb-derived OECs	43890
host spinal cord for 2 to 8 months -LRB- Li et al. , 1998 ; Ramon - Cueto , 2000 ; Takami et al. , 2002 -RRB-	43911
host spinal cord	43911
2 to 8 months -LRB- Li et al. , 1998 ; Ramon - Cueto , 2000 ; Takami et al. , 2002 -RRB-	43932
2 to 8 months	43932
Li	43947
et al. , 1998 ; Ramon - Cueto , 2000 ; Takami et al. , 2002	43950
et al.	43950
1998 ; Ramon - Cueto , 2000 ; Takami et al.	43958
1998 ; Ramon	43958
1998	43958
Ramon	43964
Cueto , 2000	43971
Cueto	43971
2000	43978
Takami et al.	43984
Takami	43984
et al.	43991
2002	43999
These differences	44006
inherent problems in the use of dye labeling to track cells or to distinct differences in the adaptability of bulb-derived versus mucosa-derived OECs in the spinal cord	44040
inherent problems	44040
the use of dye labeling to track cells or to distinct differences in the adaptability of bulb-derived versus mucosa-derived OECs in the spinal cord	44061
the use	44061
track cells	44088
distinct differences in the adaptability of bulb-derived versus mucosa-derived OECs in the spinal cord	44106
distinct differences	44106
the adaptability of bulb-derived versus mucosa-derived OECs in the spinal cord	44130
the adaptability	44130
bulb-derived versus mucosa-derived OECs in the spinal cord	44150
bulb-derived	44150
mucosa-derived OECs in the spinal cord	44170
mucosa-derived OECs	44170
the spinal cord	44193
endogenous eGFP fluorescence	44219
the fate of the transplanted LP-OECs	44284
the fate	44284
the transplanted LP-OECs	44296
their migration	44322
a GFP filter	44372
the lowest magnification available -LRB- 25 -RRB- , and migration routes delineated microscopically -LRB- Fig. 1 -RRB-	44388
the lowest magnification	44388
25	44424
migration routes delineated microscopically -LRB- Fig. 1 -RRB-	44434
migration routes	44434
Fig. 1	44479
an initial migration down radially aligned channels into the host cord surrounding the lesion site	44496
an initial migration	44496
channels	44539
the host cord surrounding the lesion site	44553
the host cord	44553
the lesion site	44579
the persistence of mouse LP-OECs at the rat lesion site	44596
the persistence	44596
mouse LP-OECs at the rat lesion site	44615
mouse LP-OECs	44615
the rat lesion site	44632
LP-OECs	44669
28 to 60 days	44701
the rat spinal cord	44744
60 days	44767
transplantation	44781
mouse LP-OECs	44809
a mouse-lesion site	44845
the relatively poor survival of mouse LP-OECs	44866
the relatively poor survival	44866
mouse LP-OECs	44898
part	44936
an acute rejection response to xenotransplanted cells , despite treatment with cyclosporin A. Alternatively , LP-OECs might not adapt as well as OB-OECs to migrating through a CNS environment	44945
an acute rejection response	44945
cells	44993
treatment with cyclosporin A. Alternatively , LP-OECs might not adapt as well as OB-OECs to migrating through a CNS environment	45008
treatment	45008
cyclosporin A. Alternatively , LP-OECs might not adapt as well as OB-OECs to migrating through a CNS environment	45023
cyclosporin A. Alternatively , LP-OECs might not adapt	45023
cyclosporin A.	45023
LP-OECs	45053
OB-OECs to migrating through a CNS environment	45088
OB-OECs	45088
a CNS environment	45117
this reason	45140
rat OB-OECs transplanted into a similar rat lesion	45183
rat OB-OECs	45183
a similar rat lesion	45213
a similar limited migration pattern	45252
transplantation -LRB- Li et al. , 2003 -RRB-	45294
transplantation	45294
Li	45311
et al. , 2003	45314
et al.	45314
2003	45322
The majority of published OEC transplant experiments that have reported more extensive migration and survival	45329
The majority	45329
published OEC transplant experiments that have reported more extensive migration and survival	45345
published OEC transplant experiments	45345
more extensive migration and survival	45401
the fate of transplanted OECs -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 ; Ramon-Cueto et al. , 1998 ; Imaizumi et al. , 2000a , b ; Ramon-Cueto et al. , 2000 ; Boruch et al. , 2001 ; Lu et al. , 20012002 ; Verdu et al. , 2001 ; Nash et al. , 2002 -RRB-	45476
the fate	45476
transplanted OECs -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 ; Ramon-Cueto et al. , 1998 ; Imaizumi et al. , 2000a , b ; Ramon-Cueto et al. , 2000 ; Boruch et al. , 2001 ; Lu et al. , 20012002 ; Verdu et al. , 2001 ; Nash et al. , 2002 -RRB-	45488
transplanted OECs	45488
Ramon-Cueto and Nieto-Sampedro , 1994 ; Ramon-Cueto et al. , 1998 ; Imaizumi et al. , 2000a , b ; Ramon-Cueto et al. , 2000 ; Boruch et al. , 2001 ; Lu et al. , 20012002 ; Verdu et al. , 2001 ; Nash et al. , 2002	45507
Ramon-Cueto and Nieto-Sampedro	45507
1994 ; Ramon-Cueto et al. , 1998 ; Imaizumi et al. , 2000a , b ; Ramon-Cueto et al. , 2000 ; Boruch et al. , 2001 ; Lu et al. , 20012002 ; Verdu et al. , 2001 ; Nash et al.	45539
1994	45539
Ramon-Cueto et al. , 1998 ; Imaizumi et al. , 2000a , b ; Ramon-Cueto et al. , 2000 ; Boruch et al. , 2001 ; Lu et al. , 20012002 ; Verdu et al. , 2001 ; Nash et al.	45545
Ramon-Cueto	45545
et al. , 1998 ; Imaizumi et al. , 2000a , b ; Ramon-Cueto et al. , 2000 ; Boruch et al. , 2001 ; Lu et al. , 20012002 ; Verdu et al. , 2001 ; Nash et al.	45557
et al. , 1998	45557
et al.	45557
1998	45565
Imaizumi et al. , 2000a , b	45571
Imaizumi	45571
et al. , 2000a , b	45580
et al.	45580
2000a	45588
b	45594
Ramon-Cueto et al. , 2000	45597
Ramon-Cueto	45597
et al. , 2000	45609
et al.	45609
2000	45617
Boruch et al. , 2001	45623
Boruch	45623
et al. , 2001	45630
et al.	45630
2001	45638
Lu et al. , 20012002	45644
Lu	45644
et al. , 20012002	45647
et al.	45647
20012002	45655
Verdu et al. , 2001	45665
Verdu	45665
et al. , 2001	45671
et al.	45671
2001	45679
Nash et al.	45685
Nash	45685
et al.	45690
2002	45698
These approaches	45705
potential diffusion of the dye , rendering transplanted cells false negative and , perhaps more importantly , other cells false positive -LRB- Iwashita et al. , 2000 -RRB-	45746
potential diffusion	45746
the	45769
transplanted cells false negative and , perhaps more importantly , other cells false	45788
transplanted cells	45788
other cells	45853
Iwashita	45881
et al. , 2000	45890
et al.	45890
2000	45898
addition	45908
the habitual use of p75 immunodetection to identify transplanted OECs in the spinal cord in vivo	45918
the habitual use	45918
p75 immunodetection	45938
transplanted OECs	45970
the spinal cord in vivo	45991
the spinal cord	45991
vivo	46010
the light of our discovery of a significant population of endogenous Schwann cells	46036
the light	46036
our discovery of a significant population of endogenous Schwann cells	46049
our discovery	46049
a significant population of endogenous Schwann cells	46066
a significant population	46066
endogenous Schwann cells	46094
p75 drawn into the spinal cord after LP-OEC transplantation -LRB- Figs. 2 , 6 ; Li et al. , 1997 , 1998 ; Takami et al. , 2002 -RRB-	46144
p75	46144
the spinal cord	46159
LP-OEC transplantation -LRB- Figs. 2 , 6 ; Li et al. , 1997 , 1998 ; Takami et al. , 2002 -RRB-	46181
LP-OEC transplantation	46181
Figs. 2 , 6 ; Li et al. , 1997 , 1998 ; Takami et al. , 2002	46205
Figs. 2	46205
Figs.	46205
2	46211
6 ; Li et al.	46214
6	46214
Li et al.	46217
Li	46217
et al.	46220
1997	46228
1998 ; Takami et al. , 2002	46234
1998	46234
Takami et al. , 2002	46240
Takami	46240
et al. , 2002	46247
et al.	46247
2002	46255
LP-OECs	46262
cavity and scar formation It is evident that , regardless of their limited survival after transplantation , LP-OECs dramatically modify the spinal cord lesion environment in several ways to counteract normal barriers to regeneration	46279
cavity and scar formation	46279
It	46305
their limited survival after transplantation	46339
their limited survival	46339
transplantation	46368
LP-OECs	46385
the spinal cord lesion environment in several ways	46413
the spinal cord lesion environment	46413
several ways	46451
normal barriers	46478
regeneration	46497
One of the most dramatic results of OEC transplantation	46511
One	46511
the most dramatic results of OEC transplantation	46518
the most dramatic results	46518
OEC transplantation	46547
the lack of cavity at the lesion site -LRB- Figs. 1 , 2 -RRB-	46571
the lack	46571
cavity at the lesion site -LRB- Figs. 1 , 2 -RRB-	46583
cavity	46583
the lesion site -LRB- Figs. 1 , 2 -RRB-	46593
the lesion site	46593
Figs. 1	46610
2	46619
Cavities , such as those seen in control rats ,	46623
Cavities	46623
those seen in control rats	46641
those	46641
control rats	46655
a major obstacle	46684
axonal regeneration	46704
axons	46728
a growth substrate for elongation	46742
a growth substrate	46742
elongation	46765
cavities in rats	46785
cavities	46785
rats	46797
those in humans	46820
those	46820
humans	46829
their formation	46848
a significant step toward successful treatment of human SCI -LRB- reviewed in Schwab , 2002 -RRB-	46871
a significant step	46871
successful treatment of human SCI -LRB- reviewed in Schwab , 2002 -RRB-	46897
successful treatment	46897
human SCI	46921
Schwab , 2002	46944
Schwab	46944
2002	46952
7 days	46971
LP-OEC transplantation	46984
rat p75-positive host Schwann cells	47008
rat	47008
p75-positive host Schwann cells	47012
the core of the lesion	47056
the core	47056
the lesion	47068
the marginal zone of the cell transplant -LRB- Fig. 2 -RRB-	47099
the marginal zone	47099
the cell transplant -LRB- Fig. 2 -RRB-	47120
the cell transplant	47120
Fig. 2	47141
OECs	47153
the lesion core	47177
Schwann cells	47194
laminin-rich channels	47216
the host	47254
spinal cord , similar to those outlined by the early migrating OECs	47263
spinal cord	47263
those outlined by the early migrating OECs	47287
those	47287
the early migrating OECs	47305
Schwann cells	47340
lesioned spinal cord -LRB- Brook et al. , 1998 -RRB-	47388
lesioned spinal cord	47388
Brook	47410
et al. , 1998	47416
et al.	47416
1998	47424
their progress	47431
the hostile environment of the lesion site	47468
the hostile environment	47468
the lesion site	47495
they	47515
the control spinal cords showed very limited Schwann cell invasion -LRB- Figs. 2 , 6 -RRB-	47562
the control spinal cords showed very limited Schwann cell invasion	47562
the control	47562
spinal cords	47574
very limited Schwann cell invasion	47594
Figs. 2	47630
6	47639
we	47643
OECs	47660
a CNS environment that facilitates migration and integration of infiltrating Schwann cells	47678
a CNS environment	47678
migration and integration of infiltrating Schwann cells	47713
migration and integration	47713
Schwann cells	47755
Schwann cells	47770
the cellular substrate for successful regeneration in the PNS	47788
the cellular substrate	47788
successful regeneration in the PNS	47815
successful regeneration	47815
the PNS	47842
minichannels	47871
regeneration	47893
Martini , 1994 ; Fu and Gordon , 1997	47924
Martini	47924
1994 ; Fu and Gordon	47933
1994	47933
Fu and Gordon	47939
1997	47954
Schwann cell and peripheral nerve transplantation strategies	47961
Schwann cell	47961
peripheral nerve transplantation strategies	47978
considerable promise	48033
repair of a variety of SCI models	48057
repair	48057
a variety of SCI models	48067
a variety	48067
SCI models	48080
they	48097
the regeneration of sensory , propriospinal , and brainstem spinal neurons -LRB- Martin et al. , 19911996 ; Xu et al. , 1997 -RRB-	48114
the regeneration	48114
sensory , propriospinal , and brainstem spinal neurons -LRB- Martin et al. , 19911996 ; Xu et al. , 1997 -RRB-	48134
sensory , propriospinal , and brainstem spinal neurons	48134
brainstem	48162
Martin	48188
et al. , 19911996 ; Xu et al. , 1997	48195
et al.	48195
19911996 ; Xu et al.	48203
19911996	48203
Xu et al.	48213
Xu	48213
et al.	48216
1997	48224
addition to being effective in several remyelination strategies -LRB- reviewed in Kocsis et al. , 2002 -RRB-	48234
addition	48234
several remyelination strategies -LRB- reviewed in Kocsis et al. , 2002 -RRB-	48265
several remyelination strategies	48265
Kocsis	48311
et al. , 2002	48318
et al.	48318
2002	48326
these cases	48345
the re-entry of regenerating axons from the Schwann cells	48358
the re-entry	48358
axons	48387
the Schwann cells	48398
the host spinal cord has been limited	48428
the host	48428
spinal cord	48437
Schwann cell transplantation	48467
OB-OEC grafts	48524
the spinal cord interface	48541
better axonal regeneration	48581
Schwann cell cables in a transection -LRB- Ramon-Cueto et al. , 1998 ; Takami et al. , 2002 -RRB-	48616
Schwann cell cables	48616
a transection -LRB- Ramon-Cueto et al. , 1998 ; Takami et al. , 2002 -RRB-	48639
a transection	48639
Ramon-Cueto	48654
et al. , 1998 ; Takami et al. , 2002	48666
et al.	48666
1998 ; Takami et al.	48674
1998	48674
Takami et al.	48680
Takami	48680
et al.	48687
2002	48695
a contusion model -LRB- Ramon-Cueto et al. , 1998 ; Takami et al. , 2002 -RRB-	48713
a contusion model	48713
Ramon-Cueto	48732
et al. , 1998 ; Takami et al. , 2002	48744
et al.	48744
1998 ; Takami et al.	48752
1998	48752
Takami et al.	48758
Takami	48758
et al.	48765
2002	48773
Our results	48780
lesions where host Schwann cells can access the lesion site	48810
lesions	48810
host Schwann cells	48824
the lesion site	48854
OECs	48871
them	48890
an environment that is conducive to both axonal growth and modification of the graft -- host glial interface	48906
an environment	48906
both axonal growth and modification of the graft	48942
both axonal growth and modification	48942
the graft	48981
host glial interface	48991
The dense glial scar normally formed around the cavity of a spinal cord lesion	49013
The dense glial scar	49013
the cavity of a spinal cord lesion	49057
the cavity	49057
a spinal cord lesion	49071
a major barrier	49106
regeneration -LRB- reviewed in Fawcett , 2002 -RRB-	49125
regeneration	49125
Fawcett , 2002	49151
Fawcett	49151
2002	49160
the tight pericavity boundary characteristic of glial scar formation	49192
the tight pericavity boundary characteristic	49192
glial scar formation	49240
GFAP-positive astrocytes	49262
a wide , diffuse permeabilized matrix around the LP-OECs	49292
a wide , diffuse permeabilized matrix	49292
the LP-OECs	49336
the rostrocaudal channels formed by invading LP-OECs -LRB- Fig. 3 -RRB-	49364
the rostrocaudal channels	49364
LP-OECs -LRB- Fig. 3 -RRB-	49409
LP-OECs	49409
Fig. 3	49418
This astrocytic network	49427
finger-like projections pointing toward the lesion center that interdigitate with invading Schwann cells and allow descending spinal tracts to cross the distal lesion -- host interface	49465
finger-like projections	49465
the lesion center that interdigitate with invading Schwann cells and allow descending spinal tracts to cross the distal lesion -- host interface	49505
the lesion center	49505
Schwann cells	49556
spinal tracts	49591
the distal lesion -- host interface	49614
the distal lesion	49614
host interface	49632
This organization	49648
the establishment of the developing PNS : CNS transitional zone -LRB- Fraher , 1999 -RRB-	49691
the establishment of the developing PNS	49691
the establishment	49691
the developing PNS	49712
CNS transitional zone -LRB- Fraher , 1999 -RRB-	49731
CNS	49731
transitional zone -LRB- Fraher , 1999 -RRB-	49735
transitional zone	49735
Fraher , 1999	49754
Fraher	49754
1999	49762
Glial scar permeability	49769
the expression of CSPGs , which are generally considered inhibitory to neurite outgrowth , around OECtreated lesions -LRB- McKeon et al. , 1995 ; Anderson et al. , 1998 ; Bradbury et al. , 2002 -RRB-	49813
the expression	49813
CSPGs , which are generally considered inhibitory to neurite outgrowth , around OECtreated lesions -LRB- McKeon et al. , 1995 ; Anderson et al. , 1998 ; Bradbury et al. , 2002 -RRB-	49831
CSPGs	49831
neurite outgrowth	49883
OECtreated lesions -LRB- McKeon et al. , 1995 ; Anderson et al. , 1998 ; Bradbury et al. , 2002 -RRB-	49909
OECtreated lesions	49909
McKeon et al. , 1995 ; Anderson et al. , 1998 ; Bradbury et al. , 2002	49929
McKeon	49929
et al. , 1995 ; Anderson et al. , 1998 ; Bradbury et al. , 2002	49936
et al. , 1995	49936
et al.	49936
1995	49944
Anderson et al. , 1998	49950
Anderson	49950
et al. , 1998	49959
et al.	49959
1998	49967
Bradbury et al. , 2002	49973
Bradbury	49973
et al. , 2002	49982
et al.	49982
2002	49990
CSPG production	50006
the pattern of CSPG deposition	50061
the pattern	50061
CSPG deposition	50076
diffuse deposits	50107
the lesion	50141
astrocytes	50175
the more tangential barriers of a dense scar	50197
the more tangential barriers	50197
a dense scar	50229
LP-OECs , astrocytes , and Schwann cells	50243
LP-OECs	50243
astrocytes	50252
Schwann cells	50268
a novel glial microenvironment Changes in local ECM composition	50287
a novel glial microenvironment Changes	50287
local ECM composition	50329
arrangement	50355
both astrocytes and their associated CSPGs	50381
both astrocytes	50381
their associated CSPGs	50401
neurite outgrowth -LRB- Ard et al. , 1991 ; Emerling and Lander , 1996 -RRB-	50467
neurite outgrowth -LRB- Ard et al.	50467
neurite outgrowth	50467
Ard et al.	50486
Ard	50486
et al.	50490
1991 ; Emerling and Lander , 1996 -RRB-	50498
1991	50498
Emerling and Lander , 1996	50504
Emerling	50504
Lander , 1996	50517
Lander	50517
1996	50525
The directed alignment of astrocytes along laminin richchannels radiating from the OEC-treated lesion site into the host tissue , and dispersed CSPG deposition ,	50532
The directed alignment	50532
astrocytes along laminin richchannels	50558
astrocytes	50558
laminin richchannels	50575
the OEC-treated lesion site	50611
the host tissue	50644
CSPG deposition	50675
at least part of the mechanism of OEC action	50714
at least part	50714
the mechanism of OEC action	50731
the mechanism	50731
OEC action	50748
permissive matrix	50777
the local environment	50819
inhibitory to supportive of regeneration	50846
inhibitory to supportive	50846
regeneration	50874
This finding	50888
the glial interrelationships observed in vitro , where clear boundaries are established that limit the areas of direct interaction that OECs and astrocytes may have -LRB- Van Den Pol and Santarelli , 2003 -RRB-	50909
the glial interrelationships	50909
clear boundaries	50963
limit	51001
the areas of direct interaction that OECs and astrocytes may have	51007
the areas	51007
direct interaction	51020
OECs and astrocytes	51044
Van Den Pol and Santarelli , 2003	51074
Van Den Pol and Santarelli	51074
2003	51102
invasion of host Schwann cells	51136
invasion	51136
host Schwann cells	51148
LP-OEC transplantation	51168
the groundwork	51206
a permissive PNS environment	51234
the site of SCI	51266
the site	51266
SCI	51278
this local environment	51286
reactive astrocytes and CSPGs	51310
significant barriers	51354
regeneration	51378
channels that allow in-growth of multiple brainstem spinal tracts -LRB- Figs. 4 , 7 -RRB-	51412
channels	51412
in-growth of multiple brainstem	51432
in-growth	51432
multiple brainstem	51445
spinal tracts	51464
Figs. 4	51479
7	51488
LP-OECs	51492
differential axonal sprouting and regeneration The permissive environment created by LP-OEC transplantation did promote in-growth and a regeneration response in both serotonin - and TH-positive axons -LRB- Fig. 4 -RRB-	51507
differential axonal sprouting	51507
regeneration The permissive environment created by LP-OEC transplantation did promote in-growth	51541
regeneration	51541
The permissive environment created by LP-OEC transplantation	51554
The permissive environment	51554
LP-OEC transplantation	51592
in-growth	51627
a regeneration response in both serotonin - and TH-positive axons -LRB- Fig. 4 -RRB-	51641
a regeneration response	51641
both serotonin - and TH-positive axons -LRB- Fig. 4 -RRB-	51668
both serotonin	51668
TH-positive axons	51688
Fig. 4	51707
The growth of 5HT-positive axons in and through the lesion site observed in this study -LRB- i.e. , with transplantation of purified cultures of LP-OECs -RRB-	51716
The growth	51716
5HT-positive axons in and through the lesion site observed in this study	51730
5HT-positive axons	51730
the lesion site observed in this study	51764
the lesion site	51764
this study	51792
i.e. , with transplantation of purified cultures of LP-OECs	51804
i.e.	51804
with transplantation of purified cultures of LP-OECs	51810
transplantation	51815
purified cultures of LP-OECs	51834
purified cultures	51834
LP-OECs	51855
that reported after transplantation of heterogeneous strips of olfactory mucosa -LRB- Lu et al. , 2001 -RRB-	51878
that	51878
transplantation of heterogeneous strips of olfactory mucosa -LRB- Lu et al. , 2001 -RRB-	51898
transplantation	51898
heterogeneous strips of olfactory mucosa -LRB- Lu et al. , 2001 -RRB-	51917
heterogeneous strips	51917
olfactory mucosa -LRB- Lu et al. , 2001 -RRB-	51941
olfactory mucosa	51941
Lu	51959
et al. , 2001	51962
et al.	51962
2001	51970
Serotonin and other biogenic amines	51977
Serotonin	51977
other biogenic amines	51991
rhythmic locomotor activity , presumably by means of a central pattern generator , in cats and rodents -LRB- Gerin et al. , 1995 -RRB-	52050
rhythmic locomotor activity	52050
means of a central pattern generator	52093
means	52093
a central pattern generator	52102
cats and rodents -LRB- Gerin et al. , 1995 -RRB-	52134
cats and rodents	52134
Gerin	52152
et al. , 1995	52158
et al.	52158
1995	52166
a regeneration response in 5HT-positive axons	52179
a regeneration response	52179
5HT-positive axons	52206
the functional recovery observed in an open field locomotion test -LRB- Lu et al. , 2002 -RRB-	52260
the functional recovery	52260
an open field locomotion test -LRB- Lu et al. , 2002 -RRB-	52296
an open field locomotion test	52296
Lu	52327
et al. , 2002	52330
et al.	52330
2002	52338
the same kind of robust regeneration	52360
the same kind	52360
robust regeneration	52377
this model for lesioned rubrospinal axons	52413
this model	52413
lesioned rubrospinal axons	52428
Rubrospinal neurons	52456
massive atrophy	52493
2 weeks	52509
axotomy	52523
the expression of regeneration associated genes -LRB- Kobayashi et al. , 1997 -RRB-	52549
the expression	52549
regeneration associated genes	52567
Kobayashi	52598
et al. , 1997	52608
et al.	52608
1997	52616
The initial apparent withdrawal of rubrospinal axons from the site of lesion/transplant during the first week after surgery	52623
The initial apparent withdrawal	52623
rubrospinal axons from the site of lesion/transplant during the first week after surgery	52658
rubrospinal axons	52658
the site of lesion/transplant during the first week after surgery	52681
the site	52681
lesion/transplant during the first week after surgery	52693
lesion/transplant	52693
the first week after surgery	52718
the first week	52718
surgery	52739
most likely limit their access	52753
most likely limit	52753
their access	52771
presumed OEC-derived trophic factors -LRB- Fig. 5 -RRB-	52787
presumed OEC-derived trophic factors	52787
Fig. 5	52825
The subsequent massive invasion of Schwann cells	52834
The subsequent massive invasion	52834
Schwann cells	52869
the local availability of trophic factors	52905
the local availability	52905
trophic factors	52931
rubrospinal axons	52960
the lesion site	53001
The inability of the rubrospinal axons to cross the distal lesion host interface	53018
The inability	53018
the rubrospinal axons to cross the distal lesion host interface	53035
the distal lesion host interface	53066
the failure of the parent cell bodies	53121
the failure	53121
the parent cell bodies	53136
a regenerative response for several weeks	53170
a regenerative response	53170
several weeks	53198
injury	53218
This transient preparedness of rubrospinal neurons to regenerate	53226
This transient preparedness	53226
rubrospinal neurons	53257
brain-derived neurotrophic factor -LRB- BDNF -RRB-	53309
brain-derived neurotrophic factor	53309
BDNF	53344
secreting fibroblasts	53350
rubrospinal regeneration	53385
acute -LRB- Liu et al. , 2002 -RRB- but not chronic -LRB- 4 weeks -RRB- lesion -LRB- Jin et al. , 2002 -RRB-	53416
acute -LRB- Liu et al. , 2002 -RRB- but not chronic -LRB- 4 weeks -RRB- lesion	53416
Liu et al. , 2002	53423
Liu	53423
et al.	53427
2002	53435
4 weeks	53458
Jin	53475
et al. , 2002	53479
et al.	53479
2002	53487
rubrospinal neurons	53505
peripheral nerve transplants	53549
these	53583
4 weeks	53601
lesion	53615
Houle , 1991	53623
Houle	53623
1991	53630
this failure	53641
trophic support	53689
the cell body -LRB- Kwon et al. , 2002 -RRB-	53717
the cell body	53717
Kwon	53732
et al. , 2002	53737
et al.	53737
2002	53745
LP-OECs	53752
angiogenesis The transplantation of LP-OECs not only minimizes tissue loss and prevents cavity and scar formation at the lesion site but stimulates extensive angiogenesis at the lesion site	53767
angiogenesis	53767
The transplantation of LP-OECs	53780
The transplantation	53780
LP-OECs	53803
tissue loss	53830
cavity and scar formation	53855
the lesion site	53884
extensive angiogenesis	53915
the lesion site	53941
means of secretion of VEGF synthesized by LP-OECs -LRB- Au and Roskams , 2003 ; Fig. 6 -RRB-	53970
means	53970
secretion of VEGF synthesized by LP-OECs -LRB- Au and Roskams , 2003 ; Fig. 6 -RRB-	53979
secretion	53979
VEGF synthesized by LP-OECs -LRB- Au and Roskams , 2003 ; Fig. 6 -RRB-	53992
VEGF	53992
LP-OECs -LRB- Au and Roskams , 2003 ; Fig. 6 -RRB-	54012
LP-OECs	54012
Au and Roskams	54021
Au	54021
Roskams	54028
2003 ; Fig. 6	54037
2003	54037
Fig. 6	54043
Angiogenesis and reperfusion	54052
only essential components of a mechanism to repair any damaged tissue but have already been shown to correlate with enhanced behavioral recovery after contusion SCI -LRB- Loy et al. , 2002 -RRB-	54089
only essential components	54089
a mechanism to repair any damaged tissue but have already been shown to correlate with enhanced behavioral recovery after contusion SCI -LRB- Loy et al. , 2002 -RRB-	54118
any damaged tissue	54140
enhanced behavioral recovery after contusion SCI -LRB- Loy et al. , 2002 -RRB-	54205
enhanced behavioral recovery	54205
contusion SCI -LRB- Loy et al. , 2002 -RRB-	54240
contusion SCI	54240
Loy	54255
et al. , 2002	54259
et al.	54259
2002	54267
These newly formed blood vessels	54274
a laminin-rich basal lamina that also includes the collagen V isoform p200 -LRB- Chernousov et al. , 1999 , 2000 -RRB- , a secreted glycoprotein induced in Schwann cells during regeneration by axon -- glial contact	54323
a laminin-rich basal lamina	54323
the collagen V isoform p200 -LRB- Chernousov et al. , 1999 , 2000 -RRB- , a secreted glycoprotein induced in Schwann cells during regeneration by axon --	54370
the collagen V isoform p200	54370
Chernousov	54399
et al. , 1999 , 2000	54410
et al.	54410
1999	54418
2000	54424
a secreted glycoprotein induced in Schwann cells during regeneration by axon	54431
a	54431
glycoprotein induced in Schwann cells during regeneration by axon	54442
glycoprotein	54442
Schwann cells	54466
regeneration	54487
axon	54503
glial contact	54508
This basal lamina deposition	54523
the migration path of LP-OECs and/or Schwann cells	54577
the migration path	54577
LP-OECs and/or Schwann cells	54599
LP-OECs	54599
Schwann cells	54614
a favorable substrate for neurite extension -LRB- Fig. 6 -RRB-	54648
a favorable substrate	54648
neurite extension -LRB- Fig. 6 -RRB-	54674
neurite extension	54674
Fig. 6	54693
Allotransplantation of GFP LP-OECs into strainmatched C57/Bl6 mice	54702
Allotransplantation	54702
GFP LP-OECs into strainmatched C57/Bl6 mice	54725
GFP LP-OECs	54725
strainmatched C57/Bl6 mice	54742
LP-OECs	54777
a similar mechanism	54793
regeneration	54824
the host	54851
LP-OECs	54869
a more amenable host -LRB- Fig. 7 -RRB-	54900
a more amenable host	54900
Fig. 7	54922
cavitation	54940
this mouse strain	54969
the glial scar in the presence of LPOECs	54988
the glial scar	54988
the presence of LPOECs	55006
the presence	55006
LPOECs	55022
Schwann cells	55069
the lesion core	55100
an environment permissive for regeneration	55138
an environment permissive	55138
regeneration	55168
the core of the lesion	55184
the core	55184
the lesion	55196
control mice even without cavitation	55211
control mice	55211
cavitation	55237
the dense , astrocytic-rich barrier and lack of Schwann cell infiltration	55249
the dense , astrocytic-rich barrier and lack	55249
Schwann cell infiltration	55296
the axons	55348
the lesion center	55372
the medium-injected mice	55393
the treated animals	55427
considerable axon growth throughout the lesioned area	55451
considerable axon growth	55451
the lesioned area	55487
the encouraging and largely positive regeneration effects reported so far	55523
the encouraging and largely positive regeneration	55523
effects	55573
it	55598
the sensory axon sprouting we detect into the lesion site	55620
the sensory axon	55620
we	55647
the lesion site	55662
Fig. 5	55709
significant hyperalgesia	55729
inappropriate stimulation of sensory sprouting in both animal and human experimentation	55772
inappropriate stimulation	55772
sensory sprouting in both animal and human experimentation	55801
sensory	55801
both animal and human experimentation	55822
animal	55827
human experimentation	55838
this	55861
future paradigms	55900
OECs	55923
agents of transplantation -LRB- Romero et al. , 2000 -RRB-	55931
agents	55931
transplantation -LRB- Romero et al. , 2000 -RRB-	55941
transplantation	55941
Romero	55958
et al. , 2000	55965
et al.	55965
2000	55973
conclusion	55983
we	55995
the first time	56019
well-defined and reproducible LP-OECs	56039
repair of spinal cord lesion	56089
repair	56089
spinal cord lesion	56099
a xenotransplant	56127
novel mechanistic insight	56157
they	56193
this	56210
host glial cells -LRB- Schwann cells and astrocytes -RRB-	56230
host glial cells	56230
Schwann cells and astrocytes	56248
Schwann cells	56248
astrocytes	56266
tissue repair	56291
OECs	56306
cavity formation	56319
scar formation	56344
angiogenesis	56370
a permissive glial environment	56395
the lesion site	56429
axonal growth/regeneration of multiple axonal populations	56456
axonal growth/regeneration	56456
multiple axonal populations	56486
These data	56515
LPOECs	56541
prime candidates for autologous transplantation in SCI	56551
prime candidates	56551
autologous transplantation in SCI	56572
autologous transplantation	56572
SCI	56602
this approach	56611
targeted strategies	56649
axonal regeneration	56691
the successful re-targeting of axons most desired in human SCI	56714
the successful re-targeting	56714
axons most desired in human SCI	56745
axons	56745
human SCI	56767
